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ANALYZING THE IMPACT OF EGFR-INDUCED c-MET 
PHOSPHORYLATION IN NON-SMALL CELL LUNG CANCER 
Austin M. Dulak, Ph.D. 
University of Pittsburgh, 2010 
 
Background 
Lung cancer is currently the second most prevalent form of cancer in the United States 
and is the leading cause of cancer-related deaths. Currently, there are no effective 
therapies for those diagnosed in the later stages of lung cancer. The c-Met receptor is a 
potential therapeutic target for NSCLC along with its ligand, hepatocyte growth factor 
(HGF). Signaling interactions between c-Met and the mutant Epidermal Growth Factor 
Receptor (EGFR) have been studied extensively, but the biological importance of lateral 
signaling to c-Met in EGFR wild-type tumors is minimally understood.  
 
Principal Findings 
Our observations indicate that wild-type EGFR, the receptor most often found in NSCLC 
tumors, can initiate delayed c-Met activation in NSCLC cell lines. EGFR ligands induce 
accumulation of activated c-Met which begins at 8 h and continues for 48 h. This effect is 
accompanied by phosphorylation of critical c-Met tyrosine residues. Gene transcription is 
required for delayed c-Met activation; however, phosphorylation of c-Met by EGFR 
occurs without production of HGF or secretion of other factors, supporting an internal 
mechanism that is independent of c-Met ligand. Lateral signaling is blocked by two 
selective c-Met tyrosine kinase inhibitors (TKIs), PF2341066 and SU11274, or with 
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gefitinib, an EGFR TKI, suggesting kinase activities of both receptors are required for 
this effect. The c-Src pathway is essential for EGFR to c-Met communication. This 
appears to be up- and downstream of delayed c-Met activation. Pre-treatment with pan-
SFK inhibitors, PP2 and dasatinib, abolishes delayed c-Met phosphorylation. A c-Src 
dominant-negative construct reduces EGF-induced c-Met phosphorylation compared to 
control, further confirming a c-Src requirement. Additionally, delayed c-Src association 
with c-Met and prolonged c-Src activation are observed following EGF addition. 
Inhibition of c-Met with PF2341066 and siRNA decreases the EGF-induced phenotypes 
of invasion by ~86% and motility by ~81%, suggesting that delayed c-Met activation is 
utilized by EGFR to potentiate its full biological effects possibly through STAT3. 
Combined targeting of c-Met and EGFR pathways lead to increased NSCLC xenograft 
anti-tumor activity. 
 
Conclusions and Significance 
Collectively, these data provide an alternative working model of prolonged EGFR 
signaling, whereby c-Met activation in NSCLC cell lines initiated by wild-type, non-
amplified EGFR with wild-type, non-amplified c-Met maximizes EGFR-induced cell 
motility and invasion.  With the identification of this novel pathway, the studies 
presented here demonstrate that inhibition of both EGFR downstream signaling and 
EGFR lateral signaling through the EGFR-c-Src-c-Met axis might be effective in 
treatment of NSCLC. Taken together, these findings will aid in the future development of 
combination EGFR and c-Met TKI treatments in clinical trials for NSCLC tumors that 
are wild-type for both EGFR and c-Met. 
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1.0 INTRODUCTION 
 
 
1.1 Lung Cancer Incidence and Risk Factors 
 
 Lung cancer has an alarming incidence of 78.5 cases per 100,000 people per year 
with an expected 222,520 new cases in the United States alone in 2010. The leading 
cause of cancer-related death in both men and women, lung cancer-related deaths will top 
157,000 people this year [1]. In women, the number of lung cancer cases has reached a 
plateau and remains steady, while the number of male lung cancer cases have been 
decreasing steadily since the 1990’s. Despite this decreasing trend, lung cancer is still a 
sizeable problem as evidenced by a 5-year survival rate of only 15% [1]. This suggests 
that although reducing risk factors have decreased the number of cases each year, for 
those diagnosed with lung cancer, often in its late stages, few effective therapeutic 
options exist.  
 The risk factors involved with lung tumorigenesis are well understood with the 
single greatest risk factor being tobacco product related. The most recent evaluation 
estimates that 90% of all lung cancer cases are related to primary smoke inhalation from 
cigarettes, pipes, or cigars and also environmental, second-hand smoke [1]. Moreover, 
smoking increases the risk of developing lung cancer 10-fold compared to a non-smoker, 
and this risk increases with the number cigarettes, duration of smoking, and starting age. 
Additional factors that increase lung cancer risk are other lung diseases such as chronic 
inflammation, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis 
[2]. These diseases, like smoking, are thought to contribute to lung tumorigenesis through 
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increased inflammation and cell proliferation [3]. Inhalation exposure to environmental 
agents like radon, arsenic, asbestos, chromates, chloromethyl ethers, nickel, polycyclic 
aromatic hydrocarbons as well as generalized air pollution are also known causative 
agents [4, 5]. A purely genetic link has not been fully identified for the development of 
lung tumors; however, sex differences do appear to play a significant role. Female non-
smokers have an elevated risk of developing lung cancer compared to their male 
counterparts [6]. This observation suggests that steroid hormones and their receptors, 
such as the estrogen receptor family, play a significant role in increasing susceptibility to 
lung cancer development and progression, particularly of lung adenocarcinomas [7].      
 There are two major classifications of lung carcinomas as defined by 
morphological characteristics, small cell (SCLC) and non-small cell (NSCLC), which 
NSCLC accounts for nearly 85% of cases [1]. NSCLC is further differentiated by 
histology into a number of sub-types including squamous cell carcinoma, 
adenocarcinoma, large cell carcinoma, adenosquamous carcinoma, carcinomas with 
pleopmorphic sarcomatoid, or sarcomatous elements, carcinoid tumor, carcinomas of 
salivary-glad type, and unclassified [8]. This methodology of classification provides 
pathologists and thoracic oncologists with defined characteristics by which to determine 
more effective treatment regimens. 
 
1.2 Lung Cancer Staging and Treatment 
 
 Patients with lung cancer regularly go undiagnosed until late stages of disease 
(IIIA, IIIB, or IV) due to the lack of a clearly identifiable clinical presentation. Often, 
  3 
early symptoms of lung cancer are similar to host of other illnesses such as a cough, 
wheezing, dyspnea, weight loss, and fatigue [9]. Therapeutic options for the treatment of 
lung cancer, in general, are many, but often ineffective. Currently, treatment options 
include surgical resection (lobectomy), chemoradiation, and/or chemotherapy with both 
systemic and targeted agents. The decision to utilize a certain combination of modalities 
is often defined by lung tumor stage (Table 1) [10-12].  
 
Tumor Stage Treatment Regimen 
I Surgical resection, radiation 
II Surgical resection, radiation, adjuvant chemotherapy 
IIIA Combination of surgical resection, chemotherapy, and radiation 
IIIB Chemotherapy and radiation 
IV Doublet of chemotherapy or clinical trials with novel agents 
 
Table 1. Lung tumor staging and treatment options. 
 
Tumor stage is defined by a number of characteristics including tumor size, regional 
lymph node involvement, and metastases, both regional and distant as measured by 
computed tomography (CT) screening, bronchoscopy, and occasionally magnetic 
resonance imaging (MRI) [5]. Methodology of surgical resection and chemoradiation are 
focused on removing or destroying as much of the tumor as possible, while minimizing 
damage to surrounding tissues. Chemotherapy regimens rely on the ability to destroy the 
rapidly proliferating tumor cells preferentially over normal cells with a slower rate of 
turnover.  
 Initially, lung cancer patients were treated with first-generation therapies alone 
such as platinum-based agents (cisplatin and carboplatin); however, with the emergence 
of known resistance mechanisms, these older chemotherapies are now often combined 
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with later-generation cytotoxic drugs such as taxanes (paclitaxel and docetaxel), 
vinorelbine, gemcitabine, irinotecan, and pemetrexed to produce slightly better response 
rate and improved survival. The modest improvement for these combinations was 
approximately a 15% increase in response rate and about a 1-2 month increase in survival 
[10-12]. Through these results and many others like it, it became evident that novel 
modes of therapeutic targeting were necessary to further improve patient response and 
survival time while decreasing toxic side effects. The hypothesis of a cancer “magic 
bullet” or targeted drug that is cancer-specific remained omnipresent for a long while, but 
only as recent as the 1990’s has this theory come to fruition.  
 Initial findings of cancer-targeted agents were identified in the late 1990’s when 
Brian Druker at the Ohio State University measured an exciting response to imatinib the 
ATP-competitive, tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML). 
Analysis determined that imatinib inhibited uncontrolled proliferation by blocking the 
driving force for proliferation and progression in many CML soft tumors, the protein 
tyrosine kinase fusion protein, BCR-ABL. This observation led to the purchase of 
imatinib by Novartis [13]. Since this seminal finding, there have been strong efforts to 
identify cancer-specific genes involved in tumorigenesis and progression. In the case of 
lung cancer, and NSCLC specifically, many novel targets have been identified and more 
are being measured each year. The most hopeful and promising target to date has been 
the Epidermal Growth Factor Receptor (EGFR), which is overexpressed in many cancers 
including 80-85% of NSCLC tumors [14]. Overexpression of EGFR is correlated with 
poor prognosis and decreased survival and believed to be one of the major driving forces 
in NSCLC progression through hyper-activation [15, 16].  
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1.3 Epidermal Growth Factor Receptor 
 
1.3.1 EGFR Activation and Function 
 
 EGFR (ErbB1) is a member of the structurally-related erbB family of receptor 
tyrosine kinases (RTK) that also includes HER2/Neu, HER3 and HER 4, and was named 
for the oncogene encoded by the avian erythroblastosis virus [17]. Many, if not all, 
normal epithelial cells express the mature 170 kDa ErbB1 gene product, but in NSCLC 
tumors the receptor is often overexpressed [14]. Activation of EGFR occurs not only 
through interaction with EGFR ligands epidermal growth factor (EGF), transforming 
growth factor-alpha (TGF-α), amphiregulin (AR), beta-cellulin, HB-EGF, and epiregulin, 
but also through interactions with other RTKs and G-protein coupled receptors [18, 19]. 
These interactions with EGFR ligands, probably as dimers, brings two EGFR monomers 
in close proximity to form an EGFR homodimer, or EGFR can heterodimerize with other 
monomers from the erbB family such as HER2 or HER 3 [20]. Trans-
autophosphorylation within the intracellular tyrosine kinase domain activates the tyrosine 
kinase activity of EGFR and allows for subsequent downstream tyrosine phosphorylation 
of multiple tyrosine residues in the carboxy-terminal tail. These phospho-tyrosine 
residues then serve as docking sites for interaction with Src Homology-2 (SH2) and 
phospho-tyrosine binding (PTB) domain-containing proteins such as growth factor 
receptor-bound protein 2 (Grb2), Shc, and phospholipase C-γ (PLCγ), and c-Src [21-26]. 
EGFR interaction with these adaptor molecules allows for amplification and downstream 
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transmittance of the initial activating signal to modulate central effector molecules that 
regulate cell proliferation, invasion, motility, survival, and angiogenesis such as the 
RAS/mitogen-activated protein kinase (MAPK) cascades, phosphatidylinositol 3-kinase 
(PI3K)/Akt, and signal transducer and activator of transcription (STAT) family of 
proteins (Fig. 1) [27]. Because of EGFR hyper-activation in NSCLC tumors and 
upstream involvement in many signal transduction pathways that contribute to tumor 
development and progression, many targeted drugs such as TKIs and monoclonal 
antibodies were designed to inhibit EGFR action.  
 
 
 
Figure 1. EGFR signal transduction pathway. 
 
1.3.2 EGFR Targeted Therapeutics  
 
 The chimeric monoclonal antibody, cetuximab (C-225, brand name: Erbitux), was 
the first neutralizing antibody developed to impede EGFR action in colorectal cancer 
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[28]. Binding to the extracellular domain of EGFR, cetuximab inhibits the ligand binding 
interaction between EGFR and it natural ligands preventing downstream signal 
transduction. Because this biological entity demonstrated high efficacy against colorectal 
tumors, it was moved into early phase clinical trials as a first-line treatment of NSCLC. 
Initial phase II and III trials comparing cetuximab combined with or without cisplatin and 
vinorelbine demonstrated increased response rate and a statistically significant improved 
overall survival [29]. However, additional evidence is required to gain full approval for 
the use of cetuximab in the treatment of NSCLC, and these trials are currently ongoing. 
 EGFR TKIs, to date, are the strongest and most encouraging endeavors into 
blocking EGFR signaling in NSCLC tumors. In 2003, the FDA approved gefitinib 
(ZD1839, brand name: Iressa) for the treatment of advanced NSCLC after other treatment 
options failed [30, 31]. Developed by AstraZeneca, gefitinib is an orally available 
member of the analino-quinazoline family of molecules that reversibly competes with 
ATP at the ATP binding pocket of EGFR [32, 33]. By preventing ATP from binding to 
EGFR, EGFR tyrosine kinase activity cannot be initiated and tumorigenic signaling is 
unable to proceed. The specificity and potency of gefitinib towards EGFR activation was 
the most remarkable hallmark of this drug. EGFR activation as assessed through in vitro 
kinase assays was inhibited with an IC50 = 0.033µM. The next closest assessed targets 
were HER2, KDR, and FLT-1 that had IC50 concentrations 100-fold higher than what was 
observed with EGFR [34]. Efforts in cell and animal models provided promising results; 
however, clinical outcome did not match these preclinical expectations.  
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Figure 2. Chemical structures of gefitinib (A) and erlotinib (B). 
 
 Initially, gefitinib was utilized as a single therapy in NSCLC patients that were 
resistant to platinum-based chemotherapies and docetaxel. The results from these initial 
studies found that tumor response were about 18% with symptom improvement observed 
in 40% of patients [30, 31]. Because of these findings, gefitinib was approved for use as a 
first-line therapy combined with cytotoxic chemotherapies in NSCLC patients. 
Unfortunately, this combination regimen failed to improve overall survival, time to 
progression, or response rate compared to chemotherapy alone [35, 36]. It was later 
determined that patients with tumors with EGFR mutations benefitted from gefitinib 
therapy due to increased ATP binding pocket affinity, while tumors with EGFR wild-type 
receptor lacked sensitivity. This will be elaborated on further later in the introduction. 
Currently in the United States, gefitinib is used sparingly and is only available to patients 
that have benefitted from gefitinib therapy in the past. 
 Not long after these clinical observations, another EGFR TKI developed by 
Genentech and OSI Pharmaceuticals, erlotinib (OSI-774, brand name: Tarceva), was 
approved by the FDA for treatment of NSCLC patients that have failed at least one prior 
A B 
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chemotherapy regimen [37]. Like gefitinib, erlotinib is also an orally-available, analino-
quinazoline-derived ATP competitive EGFR inhibitor with an IC50 = 0.002 µM [38].  In 
the clinical setting, erlotinib exhibited early promise by showing significantly longer 
progression-free survival and overall survival compared with placebo in patients with 
advanced NSCLC who previously received prior chemotherapy [39]. But as with 
gefitinib, many resistance and escape pathways decreased the efficacy in large 
populations. Still, erlotinib is approved in the United States for treatment of NSCLC due 
to some evidence suggesting that EGFR wild-type tumors benefit from erlotinib 
monotherapy and is utilized in patients with EGFR activating mutations. 
 
1.3.3 EGFR Tyrosine Kinase Inhibitor Resistance 
 
 Retrospective analysis demonstrated various ways utilized by tumor cells to 
escape inhibition by EGFR TKIs including both intrinsic and acquired mechanisms. This 
is particularly important in the treatment of NSCLC tumors expressing wild-type EGFR, 
which comprises the majority of NSCLC patients, and these tumors show intrinsic 
resistance [40]. One of the most prominent modes by which cancer cells circumvent RTK 
targeted therapy is to divert critical signal transduction pathways to other RTKs. This is 
possible due to the high level of RTK redundancy that leads to activation of downstream 
pathways involved in tumor progression. Among these, RTKs such as c-Met and insulin-
like growth factor-1 receptor (IGF-1R) can activate overlapping signaling cascades to 
continually signal to effector molecules such as MAPK and Akt in the event of EGFR 
blockade [41, 42]. Also, constitutive activation of molecules downstream of EGFR can 
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cause resistance to EGFR TKIs, particularly those of the KRAS gene with mutations in 
codons 12 and 13. These activating mutations occur in 15-20% of lung cancer patients 
and are associated with poor prognosis independent of therapy [43, 44]. Tumors 
harboring KRAS activating mutations are unlikely to be sensitive to EGFR therapy as the 
tumor driving force for growth through MAPK is downstream of receptor activation [40]. 
Secondary mutations in EGFR itself also confer resistance to inhibition by either gefitinib 
or erlotinib in patients with primary EGFR mutations. The most common EGFR TKI 
resistant mutation is the T790M gatekeeper mutation that occurs in 50% of patients [45-
48]. This mutation within the ATP binding pocket of EGFR is thought to sterically block 
the binding to EGFR TKIs, but still allow binding of ATP into the ATP binding pocket, 
resulting in EGFR phosphorylation and activation. 
 More recently, MET amplification was observed as an important escape 
mechanism in NSCLC that contain EGFR mutations. MET gene amplification is a mode 
of acquired EGFR TKI resistance that expands upon the previously mentioned intrinsic 
mechanisms of overlapping pathways. EGFR and c-Met both initiate anti-apoptotic, pro-
survival signaling through the HER3 activation of the PI3K/Akt pathway in lung tumor 
cells. In the presence of EGFR inhibition, MET amplification is selected for in tumor 
cells resulting in a greater c-Met receptor density such that signaling to HER3 can 
proceed in the absence of EGFR input [42]. This mode of resistance combined with the 
EGFR T790M mutation accounts for 60-70% of all acquired EGFR TKI resistance and 
the two are not mutually exclusive [49]. For this and other reasons, c-Met along with its 
ligand, Hepatocyte Growth Factor/Scatter Factor (HGF), is being studied as a possible 
target for NSCLC therapeutic development. 
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1.4 Hepatocyte Growth Factor and c-Met 
 
1.4.1 HGF and c-Met Structure 
 
 HGF is produced and secreted by mesenchymal cells such as fibroblasts and was 
initially identified as a platelet-derived mitogen for hepatocytes and a factor capable of 
inducing epithelial cell scattering, similar to that observed during epithelial-to-
mesenchymal transition [50, 51]. The HGF gene located on chromosome 7q21.1 encodes 
a precursor HGF molecule that is cleaved to a mature form by a protease [52]. The 
activated HGF protein binds with the RTK c-Met to exert its function. 
 C-Met is a plasma membrane bound RTK encoded by the MET proto-oncogene at 
the 7q21-q31 locus that shares similar structural homology to RTKs Ron and Sea. The 
receptor is expressed in all normal epithelial cells as well as some endothelial cells [53].  
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Figure 3. Structure of c-Met and important phosphorylation sites (Ma, PC, et al. 2003). 
 
Produced as a 150 kDa polypeptide, c-Met undergoes a number of post-translational 
glycosylation steps to become the fully mature 170 kDa pro from of c-Met. The pro-c-
Met molecule is cleaved into two subunits, a 45 kDa extracellular α-chain and a 145 kDa 
β-chain that has both extracellular and intracellular domains, that are linked through a 
disulfide bridge to form the mature c-Met receptor. The binding pocket for HGF on each 
c-Met monomer consists of the α-chain and the extracellular region of the β-chain, while 
the intracellular portion of c-Met contains the juxtamembrane and tyrosine kinase 
domains (Fig. 3) [54]. 
 
 13 
1.4.2 C-Met Activation and Signal Transduction 
 
 The interaction between HGF and c-Met occurs in a paracrine, endocrine, or 
autocrine manner [50, 51, 55, 56]. In a canonical pathway, HGF ligand binding, probably 
as a dimeric molecule, brings two c-Met heterodimeric units in close proximity to induce 
trans-autophosphorylation in the tyrosine kinase domain of the intracellular β-chain of c-
Met, similar to EGFR. Specifically, the tyrosine residues Y1230, Y1234, and Y1235 are 
critical for c-Met tyrosine kinase activity [57, 58]. This activation leads to subsequent 
phosphorylation on tyrosine residues Y1349 and Y1356 in the carboxy-tail which, 
comprise the multi-substrate docking site (MSDS), is integral in c-Met function, and 
allows recruitment of effector molecules responsible for downstream signaling such as 
GRB2-associated-binding protein 1 (Gab1), PI3K, Grb2 and c-Src [54, 57-59]. 
Additionally, phosphorylation of Y1365 regulates cell morphogenesis, and Y1003 is 
important for internalization and proteosomal degradation of c-Met through interaction 
with the E3 ubiquitin ligase, c-Cbl (Fig. 3) [60]. These protein-protein interactions with 
c-Met are carried out through SH2, PTB, and Met binding domains (MBD) and are 
necessary for c-Met pathway activation. The role of the effector molecules is to diversify 
the initial phospho-c-Met signal by creating additional docking sites for effector 
molecules. 
 Signal transduction cascades activated by RTKs such as c-Met rely on 
phosphorylation, whether it be on tyrosine, serine, or threonine residues, downstream to 
activate transcription factors. In turn, these transcription factors upregulate genes critical 
for phenotypic modulation. In the case of c-Met, the phenotypic modulation takes the 
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form of a program requiring precise coordination of growth, invasion, motility, anti-
apoptosis, and angiogenesis, termed invasive growth [61]. Each individual phenotype 
typically relies heavily on compound pathways that are central to one pathway or 
molecule. For proliferation and cell growth, the critical pathway activated by RTKs is the 
Ras/MAPK cascade. This pathway ultimately is initiated in a rapid and transient manner 
and signals downstream for the activation of the Erk1/2 and upregulation of cyclin D1 
and c-Myc [62]. The integrin family, c-Src/focal adhesion kinase (FAK), upregulation of 
matrix metalloproteinases (MMPs), and downregulation of E-cadherin are key steps in 
signaling that leads to increased cell motility and invasiveness [63].  As briefly discussed 
earlier, the PI3K/Akt pathway is critical in cell survival especially to prevent anoikis [64, 
65]. HGF upregulates angiogenesis through mechanisms central to cyclooxygenase-2 
(COX-2) upregulation, vascular endothelial growth factor (VEGF), and interleukin-8 (IL-
8) production [66]. The STAT family of transcription factors including STAT3 are key 
components of multiple cellular processes such as proliferation, survival, and invasion 
[67, 68]. As a whole, these HGF/c-Met phenotypes are utilized in normal physiological 
processes, but are hijacked by tumor cells for uncontrolled invasive growth (Fig. 4). 
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Figure 4. HGF/c-Met signal transduction pathway. 
 
1.4.3 C-Met Activation through Cross-talk Mechanisms 
 
 Not only is c-Met activated in response to HGF ligand interaction, but also 
through mechanisms of cross-talk or lateral signaling from other cell surface protein 
families. Among these are G-protein coupled receptors (GPCR), integrins, class B 
plexins, CD44, Ron, HER3, and most notably, EGFR. The manner in which these 
molecules interact with and activate c-Met vary greatly, but two general modes are 
utilized: indirect and direct. For example, integrin clustering can induce HGF-
independent phosphorylation of c-Met, likely through an indirect signaling pathway, in 
mouse melanoma cells [69-72]. Cross-talk between the transmembrane protein, CD44, 
and c-Met is dependent on HGF binding. The CD44 variant 3 isoform is a heparin sulfate 
binding protein that is shown to interact on the cell surface with HGF. This interaction 
allows the presentation of HGF to c-Met [73, 74]. GPCR agonists lysophosphatidic acid 
 16 
(LPA), bradykinin, thrombin, and carbachol can induce c-Met phosphorylation through c-
Met ectodomain shedding [75]. In theory, this process of extracellular removal would 
allow the remaining intracellular c-Met fragments to dimerize resulting in c-Met trans-
autophosphorylation.  Glial cell line-derived neurotrophic factor (GDNF) can also 
activate c-Met upon interaction with its cognate receptor, RET. The mechanism 
responsible for this is central to c-Src, but c-Src is not thought to be directly 
phosphorylating c-Met [76]. As a whole, these molecules provide a representative picture 
of the various mechanisms involved in c-Met activation. It does appear that these 
interactions are necessary for cell invasion, placing c-Met as the central modulator of this 
invasive growth phenotype [77]. 
 C-Met and EGFR cross-talk has been well-documented and continues to be 
actively studied due to roles of both RTKs in oncogenic transformation and therapeutic 
development. C-Met is frequently co-expressed with EGFR family members in human 
tumors, and it has been demonstrated that these RTKs can signal to one another [75, 78-
81]. Presnell et al. first showed that c-Met could be trans-activated by EGFR in rat liver 
epithelial cells constitutively expressing TGF-α [81]. Similar studies have since observed 
this signaling in NSCLC tumor models where EGFR contains activating mutations such 
as L858R or E746-A750del [82]. Additionally, lateral signaling to c-Met from EGFR has 
been identified in EGFR wild-type models, and much of this data suggests that cross-
communication from EGFR to c-Met is dependent on EGFR or c-Met expression levels 
[83, 84]. To further validate this mechanism, Xu et al. recently demonstrated that 
induction of c-Met phosphorylation required upregulation of c-Met through EGFR-
activated hypoxia-induced factor 1-alpha (HIF-1α) in both EGFR wild-type and mutant 
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cell lines [85].  
 Depending on the cell model system employed, a wide-spanning number of 
mechanisms can initiate this cross-talk between EGFR and c-Met. In NSCLC and 
epidermal carcinoma cell lines, c-Met and EGFR are in a signaling complex as identified 
through co-immunoprecipitation studies [78, 82]. It is unclear whether this interaction 
forms a c-Met/EGFR heterodimer or whether this is an indirect complex of a c-Met 
homodimer with an EGFR homodimer. The structural requirements for c-Met 
dimerization suggest that this observed association is indirect due to lack of SEMA 
domain homology in EGFR [86]. Also, EGFR can activate cell surface proteases through 
the MAPK pathway that induce c-Met ectodomain shedding similar to GPCR activation 
of c-Met [75]. C-Src appears to play an important, yet not fully defined, role in cross-talk 
as well. Mueller et al. demonstrated that in breast cancer cells c-Met activates the non-
receptor tyrosine kinase, c-Src, which in turn can directly phosphorylate EGFR allowing 
for signal attenuation [87]. In our laboratory, we previously demonstrated that exogenous 
prostaglandin E2 (PGE2), stimulated invasion in our NSCLC model system through an 
intricate signaling axis requiring EGFR ligand production, c-Met, and the Src family 
kinases (SFK) [88]. Thus, this provides circumstantial evidence that EGFR activation of 
c-Met requires c-Src in some capacity in NSCLC. Despite these many findings, few 
studies have dissected the exact role of c-Src in EGFR/c-Met cross-talk, and the 
biological outcomes of such an interaction.   
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1.4.4 C-Met Function in Normal Tissues 
 
 In normal tissues, the HGF/c-Met pathway is critical for embryonic development 
and tissue regeneration, where both processes utilized regulated invasive growth. During 
mouse embryogenesis, HGF and c-Met are co-expressed in endodermal and mesodermal 
structures along the rostro-caudal axis [89]. HGF and c-Met are absolutely required for 
placenta and liver development and for directional migration of myoblasts from somites 
to the limbs [90]. The essential requirement for these two molecules in development is 
highlighted by separate studies demonstrating that HGF and c-Met knockout mice share 
similar phenotypes and are both embryonically lethal [91, 92].  
 Invasive growth, in adult tissues is generally quiescent; however, it can be 
reactivated by sensing organ damage when remaining cells must migrate to reconstitute 
the integrity of the injured tissues. Following injury to liver, heart, or the kidney, HGF 
levels increase in plasma due to secretion from both local and distant sites [93-96]. Upon 
tissue regeneration, the invasive growth program is canceled and HGF and c-Met levels 
decrease to basal level conditions. This cancelation process after these normal processes 
highlights the explicit difference in physiological invasive growth from uncontrolled 
invasive growth in cancer cells. 
 
1.4.5 HGF/c-Met Pathway in Cancer 
 
 HGF/c-Met dysregulated signaling has been implicated in many cancers including 
NSCLC [63]. The first evidence that c-Met activation could lead to oncogenic 
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transformation was with the identification of the translocated promoter region (TPR)-
MET fusion protein that was a product of a chromosomal rearrangement in an 
osteosarcoma cell line treated with chemical carcinogen that caused c-Met to be 
constitutively active [97]. Since then other mechanisms of dysregulation including, HGF 
and/or c-Met amplification, c-Met activating mutations, and HGF autocrine signaling 
loops were observed [98]. In the case of NSCLC, overexpression of HGF and/or c-Met is 
the leading driver of aberrant activity potentially through increased receptor 
oligomerization and ligand-independent activation [63]. Additionally, it was observed 
that certain juxtamembrane mutations in the c-Met receptor confer prolonged activation 
and signaling due to loss of the Y1003 phospho-tyrosine residue required for regulating 
internalization [99]. Aberrant activation of the HGF/c-Met pathway is uncontrolled; thus, 
this pathway is an ideal candidate for therapeutic intervention. Disruption of the HGF/c-
Met pathway by c-Met-directed siRNAs, therapeutics, and HGF antibodies decreases 
tumorigenic potential [51, 100-102]. Based on these studies and findings that the HGF/c-
Met pathway contributes to EGFR TKI resistance, there have been strong efforts to 
develop therapies to block this pathway in many cancers including NSCLC [98]. 
 
1.4.6 HGF/c-Met Targeted Therapeutics 
 
 Development of therapeutic strategies targeting the HGF/c-Met pathway is 
currently under rapid development by academic institutes and industry, alike.  The most 
common targeted molecules designed to antagonize this pathway are HGF- or c-Met-
specific monoclonal antibodies and ATP competitive inhibitors against c-Met [98, 102]. 
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Rationally designed neutralizing monoclonal antibodies directed against HGF and c-Met 
are focused on disrupting the HGF interaction with c-Met at the HGF binding pocket. 
Through disruption of this binding, c-Met activation through the canonical ligand 
pathway cannot proceed and c-Met regulated invasive growth is abolished [102]. These 
directed therapeutics are currently in the early stages of clinical trials with more being 
disclosed yearly. 
 
 
Figure 5. Chemical structures of c-Met targeted agents. 
 
To date, a majority of HGF/c-Met pathway specific inhibitors are c-Met directed TKIs 
that function similar to gefitinib and erlotinib targeting of EGFR. The initial molecule 
identified to impede c-Met activation was the staurosporine analog and Trk family 
inhibitor, K252a (Fig. 5). K252a inhibited HGF-induced cell scattering was relatively low 
at 30 nM, but also had extensive off-target effects on other tyrosine kinases such as 
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platelet-derived growth factor receptor (PDGFR) [103]. Despite, the lack of specificity of 
K252a, these findings provided a strong foundation for the development of other small 
molecule c-Met inhibitors such as SU11274, PHA665752, and PF2341066 (Fig. 5).   
 SU11274 and PHA665752 were Pfizer’s first reported c-Met ATP competitive 
inhibitors. These molecules share a similar indolin-2-one core structure with differing R-
group substitutions and are potent inhibitors of c-Met in enzymatic assays: SU11274 
IC50=0.01 µM, PHA665752 IC50=0.009 µM. The specific interaction of these inhibitors 
with c-Met is not perfectly understood, but it is known that SU11274 activity is lost in 
cells with a c-Met Y1248H mutations suggesting that interaction with the activation loop 
is key for compound activity [104]. In biochemical studies, these preclinical molecules 
can inhibit c-Met autophosphorylation in cell model systems. SU11274 blocked c-Met 
phosphorylation at a 5 µM concentration in A549 cells and, the later generation, 
PHA665752 inhibited phosphorylation at a 1 µM concentration [104, 105]. Both 
molecules also demonstrated in vivo efficacy by reducing xenograft tumor growth; 
however, both molecules failed to move into clinical trials due to lack of bioavailability 
and poor pharmaceutical properties.  
 Pfizer moved forward with development of PF2341066 (crizotinib), a more 
selective and potent c-Met inhibitor (IC50=0.004 µM). This member of the pyridine 
family also had significant specificity (IC50=0.024 µM) on the anaplastic lymphoma 
kinase (ALK). Cell-based assays demonstrated that concentrations between 5 nM and 20 
nM inhibited c-Met-dependent phenotypes of proliferation, migration, and invasion, as 
well as reduced lung xenograft tumor growth at a dosages between 6.25 mg/kg/day and 
50 mg/kg/day in multiple cancer models [106, 107]. Because of these exciting findings, 
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this inhibitor moved rapidly into clinical trials for NSCLC. In a phase I trial, PF2341066 
showed high clinical efficacy against tumors with activating ALK gene fusions or MET 
alterations [108]. Ongoing phase II and III clinical trials are currently assessing the 
efficacy of this molecule with the anticipation that it will be selectively utilized in lung 
tumors that have MET amplification or express the hyper-active Echinoderm 
microtubule-associated protein-like 4 (EML4)-ALK fusion gene. Both of these factors 
render the tumor cells highly sensitive to this agent. Concurrently, there remain strong 
efforts to identify additional molecules to target the HGF/c-Met pathway in lung cancer 
especially to combine with EGFR TKIs to circumvent resistance [42, 109, 110]. 
 
1.5 Personalized Medicine in Lung Cancer 
 
 It was initially thought that EGFR overexpression as detected by 
immunohistochemistry might correlated with EGFR TKI sensitivity; however, recent 
studies suggest that EGFR mutations in NSCLC not only render tumors resistant, but also 
can increase sensitivity to EGFR TKIs. As discussed previously, the EGFR T790M 
gatekeeper mutation decreases sensitivity of NSCLC cells to the EGFR small molecule 
inhibitors erlotinib and gefitinib. Conversely, EGFR activating mutations such as the in-
frame deletion in exon 19 (E746-A750del) and the substitution of arginine for leucine at 
position 858 (L858R) causes increased sensitivity to EGFR TKIs [48]. Approximately 
70% of tumors expressing EGFR activating mutations are sensitive to EGFR TKI 
treatment compared to a 10% response in EGFR wild-type tumors [111]. These seminal 
findings along with the improvement in sequencing technologies and proteomic profiling 
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have provided intriguing opportunities to tailor specific treatments for patients based on 
molecular characteristics of individual tumors.  
 
Figure 6. Example of NSCLC treatment algorithm. (Dempke, WCM, et al. 2010) 
 
Personalized medicine in the context of late stage (IIIA, IIIB, and IV) NSCLC is making 
progress through response analysis of patients treated with targeted agents. A present 
focus in NSCLC is to characterize the specific driving forces responsible for individual 
tumor growth. Currently, it is believed that that less than 10% of NSCLC tumors are 
driven by EGFR mutations, about 10% through KRAS mutations, 3.5% through the 
EML4-ALK fusion protein, 1.5% BRAF, 3% other (PI3K, HER2), and others yet to be 
identified [43, 112-115]. These mutations are particularly observed in lung 
adenocarcinomas. Once this profiling of tumors is more complete, it will provide 
pathologists and oncologists with a more comprehensive treatment algorithm to base 
therapeutic strategy decisions compared to the current usage of histological markers 
alone (Fig. 6). For example, a tumor with a KRAS mutation with no EGFR mutation 
would likely be resistant to any RTK targeting with c-Met and EGFR agents. Therefore, 
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an inhibitor of effector molecules downstream of KRAS such as MEK, using the inhibitor 
AZD6244, might be a more beneficial target [116] An additional example applies to 
NSCLC tumors expressing wild-type EGFR with increased c-Met activity through 
elevated HGF levels. According to this profile, the first-line course of action might be to 
combine EGFR and c-Met TKIs to inhibit tumorigenic signaling from both receptors as 
well as the known resistance development. 
  As profiling technologies become more affordable and ubiquitous, a flow-chart 
such as the one depicted here could further guide effective treatment regimens. With the 
vast number of targeted agents available for NSCLC treatment, and many more in 
development, the future focus is to identify sensitive populations of individuals that 
might respond to selective treatment. 
 
1.6 PURPOSE 
 
 It is our overall hypothesis that stimulation of c-Met through both HGF and lateral 
signaling from the EGFR pathway is important in lung cancer: 
1) Determine the mechanism by which EGFR activation of c-Met occurs. 
2) Understand the biological consequences of EGFR to c-Met communication. 
3) Investigate the advantage of combination treatment targeting c-Met and EGFR in 
a bioluminescent orthotopic murine model of NSCLC. 
Upon successful completion of the proposed aims, we will gain a better understanding of 
critical intermediates in this additional pathway that leads to c-Met activation, and this 
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knowledge will be utilized as rationale for the clinical development of novel c-Met/EGFR 
combination strategies in EGFR and c-Met wild-type NSCLC.   
 
 
1.7 MATERIALS AND METHODS 
 
 
1.7.1 Chemical Reagents 
 
Actinomycin D, SU11274, and PP2 were purchased from Calbiochem (San Diego, CA). 
Dasatinib (BMS-354825) was purchased from Chemietek (Indianapolis, IN). The c-Met 
and non-targeting siRNA ON-TARGETplus SMARTpools were purchased from 
Dharmacon (Lafayette, CO). EGF, TGF-α, HGF, HGF neutralizing antibody, and non-
immune IgG control were purchased from R&D Systems (Minneapolis, MN). 
 
1.7.2 Cell Lines and Culture Conditions 
 
NSCLC cell lines A549 and H1435 were obtained from American Type Culture 
Collection (Manassas, VA) and the 201T cell line was established in our laboratory from 
primary tissue specimens [117]. All cells were maintained at 37°C in 5% CO2. All cells 
were grown in Basal Medium Eagle (BME) or RPMI 1640 supplemented with 10% fetal 
bovine serum and 2 mM L-Glutamine. All cells were grown to 60-80% confluence in full 
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serum media and serum-deprived 48 h prior to growth factor stimulation unless otherwise 
noted. 
 
1.7.3 Protein Analysis 
 
Immunoprecipitation 
Equal amounts of protein was subjected to immunoprecipitation with indicated antibodies 
overnight at 4°C while rotating then incubated with Protein A-Agarose Beads (Thermo 
Fisher Scientific, Rockford, IL) for 2 h at 4°C. Samples were washed 3X with NP-40 
lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, pH 8.0) containing a Complete 
Mini Protease Inhibitor Cocktail Tablet  (Roche, Indianapolis, IN) and phosphatase 
inhibitors (25 mM NaF and 1.5 mM NaV) and resuspended in 2X Tris-Glycine SDS 
Sample Buffer (0.5 mM Tris-HCl, 20% Glycerol, 10% SDS, 0.1% Bromophenol Blue). 
 
Western Blotting 
Cells were washed with twice with 1X phosphate-buffered saline (PBS) and lysed with 
NP-40 lysis buffer and briefly sonicated. The insoluble fraction was cleared by 
centrifugation at 10000 x g for 15 min at 4°C. Protein concentrations were measured by 
Bradford Assay (Pierce). Equal amounts of protein were separated on Tris-Glycine SDS 
page gels under reducing conditions. Protein was transferred to nitrocellulose membrane 
followed by blocking with 5% milk, 1x Tris-Buffered Saline (TBS) with Tween 20. 
Primary antibodies were incubated in 1% milk, 1x TBS-Tween 20 at 4°C overnight. 
Secondary antibodies were horseradish peroxidase–conjugated IgG at a 1:2,000 dilution. 
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ECL Plus chemiluminescent (GE Healthcare, Piscataway, NJ) was used for detection 
followed by autoradiography. For re-probing, blots were stripped using IgG Elution 
Buffer (Thermo Fisher Scientific). Blots were quantified by densitometry and ImageJ 
analysis (National Institutes of Health, Bethesda, MD).  
 
Primary Antibodies 
Primary Antibody Species; Dilution Manufacturer 
Phospho-c-Met (Y1349) Rabbit; 1:1000 Invitrogen (Carlsbad, CA) 
Phospho-c-Met (Y1365) Rabbit; 1:1000 Invitrogen 
Phospho-c-Met (Y1003) Rabbit; 1:1000 Invitrogen 
Phospho-c-Src (Y418) Rabbit; 1:1000 Invitrogen 
Total c-Src Mouse; 1:1000 Invitrogen 
Total c-Met (C-28) Rabbit; 1:1000 Santa Cruz Biotechnology (Santa Cruz, CA) 
Total c-Src (N-16) Rabbit; 1:1000 Santa Cruz Biotechnology 
Phospho-tyrosine (pY99) Mouse; 1:750 Santa Cruz Biotechnology 
Total c-Met (C-12) Rabbit; 1:150 Santa Cruz Biotechnology 
Total Lyn Rabbit; 1:1000 Santa Cruz Biotechnology 
Total c-Met (25H2) Mouse; 1:1000 Cell Signaling (Beverly, MA) 
Phospho-EGFR (Y1068) Mouse; 1:1000 Cell Signaling 
Total EGFR Rabbit; 1:1000 Cell Signaling 
Phospho-c-Met (Y1234/35) Rabbit; 1:1000 Cell Signaling 
P44/42 MAP Kinase Rabbit; 1:1000 Cell Signaling 
Phospho- p44/42 MAP Kinase 
(E10) 
Mouse; 1:1000 Cell Signaling 
Phospho-Akt (S473) Rabbit; 1:1000 Cell Signaling 
Total Akt Rabbit; 1:1000 Cell Signaling 
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Phospho-Stat3 (Y705) Rabbit; 1:1000 Cell Signaling 
Total Stat3 Rabbit; 1:1000 Cell Signaling 
Total MMP2 Rabbit; 1:500 Santa Cruz Biotechnology 
Total MMP9 Rabbit; 1:500 Santa Cruz Biotechnology 
Total EGFR Mouse; 1:1000 
BD Transduction Laboratories (San Jose, 
CA) 
E-Cadherin Mouse; 1:500 BD Transduction Laboratories 
Total EGFR Mouse; 1:7500 Sigma-Aldrich 
β-Actin Mouse; 1:50000 Sigma-Aldrich 
Ki-67 Rabbit, 1:200 Abcam (Cambridge, MA) 
COX-2 Mouse; 1:1000 Cayman Chemicals (Ann Arbor, MI) 
 
1.7.4 Analysis of HGF Expression 
 
Human HGF ELISA 
Cell culture media was harvested and analyzed in triplicate by Quantikine Human HGF 
enzyme-linked immunosorbent assay (ELISA; R&D Systems) according to the 
manufacturer's instructions. Conditioned media from fibroblasts was used as a positive 
control for HGF levels. 
 
Quantitative Real Time-PCR 
Total RNA was extracted using the RNAeasy kit (Qiagen, Valencia, CA) according to 
manufacturer’s directions. CDNA was synthesized by reverse transcription in the 
presence of 3.5 mM MgCl2 in a thermocycler. TaqMan assay was performed in a 7700 
Sequence Detector (Applied Biosystems, Foster City, CA) with an initial denaturation of 
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12 min at 95 °C followed by 40 cycles of 15 s of denaturation at 95 °C and 60 s of 
annealing and extension at 60 °C. The primers and probes used for detection are: 
validated HGF and c-Met Taqman primer/probe mix was purchased from Applied 
Biosystems, β-GUS: forward primer (5’-CTCATTTGGAATTTGCCGATT-3’); β-GUS 
reverse primer (5’-TCAACAGTCACCGACGAGAGTGCTGG-3’); Probe (5′–3′): 
CGAGTGAAGATCCCCTTTTA. The threshold cycle (Ct) value of each gene was 
measured and the difference (ΔCt) between target gene and β -GUS (control gene) was 
calculated. The relative gene expression level was calculated as 2(−ΔCt). 
 
1.7.5 C-Src In Vitro Kinase Assay 
 
201T cells were grown to 80% confluence on 150mm and serum-deprived for 48 h. One 
plate was stimulated with EGF (50 nM) for 5 min, while another plate was unstimulated. 
After treatment, cells were lysed in NP-40 lysis buffer, protein concentrations were 
measured, and equal amounts of protein were subjected to immunoprecipitation. From 
the EGF-treated cells, total c-Src was immunoprecipitated with the AHO1152 antibody (1 
µg) and total c-Met was immunoprecipitated with SC-161 antibody (0.5 µg) from the 
unstimulated cells overnight at 4°C. These samples were then co-incubated 
simultaneously with the Protein A-Agarose Beads for 2h at 4°C. Samples were washed 
3X with NP-40 lysis buffer, 1X with HNTG Buffer (50 mM HEPES-pH 7.4, 150 mM 
NaCl, 0.1% Triton X-100, 10% Glycerol), then 1X Kinase Buffer (20 mM HEPES-pH 
7.4, 150 mM NaCl, 10% Glycerol, 10 mM MgCl2, 10 mM MnCl2). Samples were 
resuspended with 1X Kinase buffer and incubated with 0.2 mM ATP for 15 min at 37°C. 
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After the kinase reaction, 2X Tris-Glycine SDS Sample Buffer was added, samples were 
boiled, and separated on Tris-Glycine SDS page gels under reducing conditions. Protein 
was transferred to nitrocellulose membrane and phosphorylated c-Met was assessed by 
pY99 immunoblotting.  
 
1.7.6 siRNA Transient Transfection 
 
201T cells were transfected with 50 pmol of either c-Met or non-targeting siRNA pools 
using Oligofectamine (Invitrogen) for 8 h. Transfection medium was replaced overnight 
followed by experimental treatments.  
 
1.7.7 Analysis of EGF-induced NSCLC Phenotypes 
 
Motility (Wound Healing Assay) 
Cells were plated on 12-well plates, grown to a confluent monolayer, and serum-deprived 
for 24 h. Wounds were created by scraping cells and washed twice with 1X PBS. All 
treatments were applied every 24 h over the experimental time course. Three wells per 
experimental treatment were examined 10X magnification by light microscope. Migration 
distance was assessed by measuring the ability of cells to close the wound area. 
 
Cellular Invasion 
Growth Factor Reduced Matrigel-coated Transwell chambers (BD Biosciences) were 
activated in serum-free media at 37°C for 2 h prior to plating. NSCLC cells (1x104) were 
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serum-deprived for 24 h and plated on transwell chambers in 1% charcoal-stripped FBS 
containing media in the top chamber containing indicated inhibitor treatments. In the 
bottom chamber, growth factors and inhibitors were refreshed every 24 h. Non-invading 
cells in the top chamber were removed by cotton swab, and invading cells were fixed and 
stained using the Diff-Quik staining solutions according to the manufacturer's instructions 
(VWR International). The number of invading cells was counted at 10X magnification.  
 
Cell Counting Assay  
Cells were plated on 6-well plates and allowed to achieve 25% confluence. Plates were 
serum deprived for 24 h, and all treatments were applied every 24 h. After 48 h, cells 
were harvested by trypsinization and 8 fields were counted with a hemocytometer at 10X 
magnification by light microscope. Three wells per experimental treatment were 
examined.  
 
Clorometric BrdU Cell Proliferation Assay  
Cells were played at a density of 1x104 cells per well in a flat-bottom 96-well plate and 
serum deprived for 24 h. All treatments were applied every 24 h over the 48 h time 
course. For the final 2 h, BrdU labeling solution was added to each well, cells were fixed, 
stained with an anti-BrdU antibody, and analyzed in triplicate according to the 
Clorometric BrdU ELISA manufacturer's instructions (Roche).  
 
1.7.8 Construction of Bioluminescent NSCLC Cell Lines 
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Construction of pMSCVneo-Luciferase Retroviral Vector 
The firefly luciferase gene was cloned from the pGL3 luciferase vector (Promega, 
Madison, WI) into the pMSCVneo backbone (Clontech, Mountain View, CA) at 
restriction enzyme sites EcoRI (1406) and BglII (1421) in the multiple cloning site. The 
primer sequences for cloning were: forward - 5’ 
CGGGAATTCGCCACCATGGAAGACGCCAAAAA-3’ and reverse: 5’-
GCAGATCTTCATTACACGGCGATCTTTCC-3’. 
 
Production of Luciferase Retrovirus 
Luciferase or empty vector retrovirus was produced in Ampho-Pack 293 cells (Clontech) 
grown in DMEM plus 10% FBS at 37°C, 5% CO2. The vector pMSCVneo-luciferase or 
pMSCVneo (3 µg) was co-transfected with 3 µg of pAMPHO (Clontech) into Ampho-
Pack 293 cells with 3:1 ratio of Fugene (Roche) for 6 h. The growth media was replaced 
with new full serum medium after 18 h. The following day, the old medium was 
discarded and replaced with 6 mL fresh DMEM. After 24 hours, the retroviral 
supernatant was collected and replaced with 6 mL of fresh DMEM. This procedure was 
continued every 24 h for the next 2 days. All viral pools were combined and stored at -
80°C until NSCLC cells were prepared for infection. 
 
NSCLC Infection with Luciferase Retrovirus 
201T and A549 cells were grown to 50% confluence in 6-well dishes in full serum 
medium. The luciferase retroviral media collected from 293 cells was placed on NSCLC 
cells in the presence of 5 µg/mL polybrene (hexadimethrine bromide). After 4 h, the virus 
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was removed and replaced with fresh DMEM for 48 h. Cells were split at a 1:4 dilution 
and individual clones with positive expression of the firefly luciferase was selected for 
under 600 µg/mL G-418 pressure for 4 weeks.   
 
Luciferase Assay 
Luciferase or empty vector clones were grown to 80% confluence on 24-well tissue 
culture dishes and lysed with Passive Lysis Buffer (Promega). Cell lysates were injected 
with luciferin substrate and light was measured using the AutoLumat LB953 (Berthold 
Technologies, Oak Ridge, TN) luminometer. All values are expressed as relative light 
units. 
 
Implantation of Bioluminescent NSCLC Cells into Nude Mice 
Female athymic nude-Foxn1nu 4-5 week old mice were obtained from Harlan 
(Somerville, NJ) and A549 or 201T NSCLC cells were harvested and suspended in 
sterile, serum free 1X PBS.  The cells were either injected into the hind flank region of 
each mouse, two sites per mouse (1 x106 cells per site) or into the lungs via tail vein 
(1x106 per mouse). For imaging of bioluminescent cells in vivo, animals were injected 
with 2oo µL of luciferin substrate into intraperitoneal cavity. Mice were anesthetized 
with isoflurane, transferred to the imaging platform, and imaged with the Xenogen IVIS 
Imager (Caliper LifeSciences, Hopkinton, MA) every 7 days for 4 weeks. At the end of 
the growth period, the animals were sacrificed and lung blocks were removed from 
selected animals. The lungs were fixed in 10% buffered formalin for gross inspection for 
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lung tumors. Animal care was in strict compliance with the institutional guidelines 
established by the University of Pittsburgh. 
 
1.7.9 Evaluation of Combined EGFR and c-Met Therapies in a 201T Xenograft 
Model of NSCLC 
 
In vivo Tumor Xenograft Model  
40 female athymic nude-Foxn1nu 4-5 week old mice were obtained from Harlan 
(Somerville, NJ) and 201T lung tumor cells were harvested and suspended in sterile, 
serum free PBS supplemented with 50% Matrigel (BD Biosciences).  The cells were then 
injected in the hind flank region of each mouse, one site per mouse (2 x106 cells per site) 
and allowed to grow to the designated size before administration of compound.   Ten 
days after tumor implantation the mice were divided into 4 treatment groups (10 mice per 
group): (a) placebo, (b) PF2341066 (c) gefitnib  (d) PF2341066 plus gefitnib.  Treatment 
began 10 days after tumor implantation.  PF2341066 (50 mg/kg) or vehicle control (0.9% 
saline/1% Tween-80) was administered daily by oral gavage and gefitnib (150 mg/kg) 
was administered twice a week by oral gavage.  The oral gavage volume was 0.2 
mL/mouse and administered for 3 weeks for all treatment groups. Tumor size was 
measured weekly and reported as an average relative tumor volume calculated as (l x w x 
h x p)/2 (mm3), where l is the length, w is the width, and h is the height of the tumor 
measured with calipers.   At the end of the treatment period, the animals were sacrificed 
and the tumors were removed.  Half of the tumor was harvested for protein analysis and 
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the other half was fixed in 10% buffered formalin for immunohistochemical (IHC) 
analysis.  
 
Immunohistochemistry 
Following antigen retrieval, sections of paraffin-embedded tumors endogenous 
peroxidase was quenched with 3% H2O2 for 10 min, rinsed with deionized water, and 
washed with TBS buffer before staining. Tumors samples were stained with respective 
antibodies for 30 min at room temperature then with secondary biotinylated secondary 
antibody for 25 min at room temperature, followed by streptavidin-conjugated 
horseradish peroxidase and 3,3′-diaminobenzidine chromogen (Dako, Glostrup, 
Denmark). Slides were counterstained with hematoxylin for 2 min then dehydrated and 
cover-slipped. 
 
1.7.10 Statistical Analyses 
 
All values are expressed as the mean ± S.E.M. Student's t test was used for all statistical 
analyses except for the tumor xenograft experiment when an unpaired t-test with Welch's 
correction was utilized.  Significance tests were performed with a two-sided significance 
level of 0.05. 
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2.0 C-MET ACTIVATION BY EGFR IS HGF-INDEPENDENT 
 
 
2.1 INTRODUCTION 
 
 Lung cancer is devastating disease with a 5-year survival rate of 15% largely due 
to the few effective therapeutic options [1]. Initially, it was hypothesized that treating 
EGFR-expressing lung tumors with EGFR-targeted therapeutics would prove effective in 
reducing tumor growth; however, these inhibitors are only successful for the treatment of 
tumors with activating EGFR mutations, a population that represents only 10% of all 
NSCLC cases [118]. Lack of clinical efficacy was noted with one major factor being 
compensatory signaling from the HGF/c-Met pathway in EGFR mutant tumors [42]. 
Because of these escape pathways, much work is now focused on understanding c-Met 
and EGFR cross-talk and interactions to identify potential drug combinations to more 
effectively block tumor progression including the EGFR and c-Met pathways 
simultaneously. Mediators of cross-talk pathways, especially those receptor tyrosine 
kinases (RTKs) are ideal candidates due to potential intrinsic resistance through 
compensatory mechanisms such as what is observed in EGFR and c-Met.  
C-Met is frequently co-expressed with EGFR family members in human tumors 
including NSCLC and it has been demonstrated that these RTKs can signal laterally to 
one another [75, 78-80]. The mechanisms by which these interactions occur are highly 
varied. However, one finding spanning the various cell model systems including mutant 
or overexpressed EGFR is that EGFR activation of c-Met is a rapid event that often 
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occurs through the formation of transient signaling interactions. Since it is unlikely that c-
Met/EGFR heterodimer formation occurs due to lack of SEMA domain homology, there 
must be additional intermediaries involved with cross-talk. Despite the extensive body of 
literature documenting EGFR to c-Met cross-talk, these essential mediators have yet to be 
fully identified, particularly in EGFR wild-type NSCLC cell models that represent 
approximately 90% of all NSCLC cases. 
 We previously demonstrated that cellular invasion stimulated by PGE2 in our 
NSCLC model system was a delayed event that required EGFR ligand production, c-Met 
activation, and the Src family kinase (SFK) signaling [88]. Here, we extend our studies to 
test whether exogenous EGFR ligand stimulation could result in activation of c-Met in 
NSCLC expressing wild-type EGFR and c-Met receptors with no MET amplification. 
Further, we aimed to delineate the mechanism and the time course by which this lateral 
signaling occurs. 
 
2.2 RESULTS 
 
2.2.1 EGFR Ligands Induce Prolonged Phosphorylation of c-Met in NSCLC Cells. 
 
It has been demonstrated that EGFR activation contributes to c-Met tyrosine 
phosphorylation in a variety of cell models, with varying kinetic parameters [75, 85]. 
Since NSCLC commonly express both receptors, we examined whether EGFR ligands 
can induce c-Met phosphorylation in human NSCLC cell lines. 201T and A549 cells 
were chosen because of moderate expression levels of wild-type EGFR and wild-type c-
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Met, which is representative of the majority of NSCLC tumors found in patients (Fig. 7). 
C-Met is also not altered in these cells as sequencing of c-Met revealed no mutations, and 
c-Met gene is not amplified in these cell lines (data not shown).  
 
 
 
Figure 7. Total c-Met, EGFR, and c-Src expression in NSCLC cell lines. NSCLC cell lines 
(201T and A549) were analyzed for basal level expression of c-Met, EGFR, and c-Src by whole 
cell lysate immunoblotting. 
 
Analysis of activated c-Met was performed following stimulation with ligands 
EGF, TGF-α, or HGF.  Time-course analysis of EGF and TGF-α treated 201T cells 
revealed that c-Met phosphorylation first appears at 8 h and is sustained for 48 h, while 
EGFR phosphorylation begins at 5 minutes and is completed by 1 h (Fig. 8a and 8b). In 
contrast, HGF stimulation induced c-Met phosphorylation that begins within 5 minutes 
and quickly terminates. (Fig. 8a). Similar results were obtained in H1435 and A549 cells 
(Fig. 8c).  
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Figure 8. EGFR ligands induce c-Met activation. (A and B) 201T cells were serum-deprived 
for 2 days prior to stimulation with EGF or TGF-α (10 nM) for 0-48 h or HGF (10 ng/mL) for 5 
min. Equal amounts of protein were immunoprecipitated with c-Met and immunoblotted with 
pY99 and total c-Met antibodies or whole lysates were probed with phospho-EGFR, total EGFR, 
c-Src, and β-Actin antibodies. (C) A549 and H1435 cells were serum-deprived for 2 days prior to 
stimulation with EGF (10 nM) for 24 h or HGF (10 ng/mL) for 5 min followed by 
immunoprecipitation with c-Met and western blotting with pY99, total c-Met, and β-Actin 
antibodies. 
 
 
2.2.2 EGFR Ligands Induce c-Met Tyrosine Phosphorylation at Y1003, Y1234/35, 
Y1349, and Y1365. 
 
The individual c-Met tyrosine residues required for activation and cell signaling 
are well characterized. The initiating event for c-Met activation is phosphorylation at 
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residues Y1230/Y1234/Y1235 followed by residues required for cell signaling such as 
Y1349, Y1365, and Y1003. To determine whether c-Met is being phosphorylated in 
response to EGFR ligands in a manner similar to that of HGF, we measured individual 
phospho-tyrosine levels of c-Met. It was confirmed that following EGF stimulation, all 
tyrosine residues analyzed on c-Met were phosphorylated and followed a pattern similar 
to HGF stimulation, albeit at delayed time points (Fig. 9a and 9b). Together, these data 
suggest a novel mode by which EGFR can regulate a prolonged, full activation of c-Met 
through increased expression levels as well as phosphorylation that persists for long 
periods.  
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Figure 9. EGF induces specific c-Met tyrosine phosphorylation similar to HGF. (A) 201T 
cells were serum-deprived for 2 days prior to stimulation with EGF (10 nM) or HGF (10 ng/mL) 
for 0-48 h followed by immunoprecipitation (IP) with c-Met. Specific c-Met phosphorylation 
sites were measured by c-Met IP then immunoblotting with phospho-c-Met antibodies: Y1003, 
Y1234/35, Y1349, and Y1365. All blots were stripped and reprobed with a total c-Met antibody 
to confirm equal loading. (B) Relative quantitation of c-Met phosphorylation compared to total c-
Met protein.  
 
2.2.3 Kinase Activities of Both EGFR and c-Met are Necessary for c-Met 
Phosphorylation Induced by EGF. 
 
To ascertain the intracellular signaling cascade responsible for c-Met 
phosphorylation, use of the EGFR tyrosine kinase inhibitor (TKI), gefitinib, was 
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employed to discern whether EGFR tyrosine kinase activity was required. Pretreatment 
with gefitinib abolished tyrosine phosphorylation of c-Met induced by EGF, while not 
inhibiting rapid c-Met tyrosine phosphorylation in response to HGF (Fig. 10a and 10b). 
These results confirmed that induction of an active EGFR by EGF was needed to 
facilitate bimodal c-Met activation. 
 
 
 
Figure 10. EGFR kinase activity is required for EGF-induced c-Met phosphorylation. 201T 
cells were serum deprived for 2 days, pretreated with indicated inhibitors, and stimulated with 
EGF (10 nM) for 24 h or HGF (10 ng/mL) for 5 min. Cell lysates were analyzed for c-Met 
tyrosine phosphorylation (pY99) and total c-Met. (A) Pretreatment with gefitinib (100 nM, 1 µM, 
10 µM) occurred for 2 h, and cells were stimulated with respective ligands. (B) Cells were 
pretreated with gefitinib (10 µM) followed by stimulation with either HGF (10 ng/mL) or EGF 
(10 nM) for 5 min.  Cell lysates were immunoprecipitated for c-Met and probed for pY99 and 
total c-Met. 
 
We next addressed whether the kinase activity of c-Met is required for the 
delayed c-Met phosphorylation. 201T cells were pretreated with selective c-Met TKIs 
SU11274 and PF2341066 and c-Met phosphorylation status was measured following 
EGF stimulation (Fig. 11a). These targeted c-Met TKIs had no effect on EGFR 
autophosphorylation induced by EGF (Fig. 11b). C-Met inhibitors ablated all c-Met 
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phosphorylation initiated by EGF, while having no effect on c-Met protein up-regulation, 
demonstrating that c-Met is not being utilized by EGFR as an adaptor-like molecule, but 
rather delayed activation of c-Met kinase activity is being used to relay the EGFR signal 
(Fig. 11a).  
 
 
 
Figure 11. C-Met kinase activity is required for EGF-induced c-Met phosphorylation. 201T 
cells were serum deprived for 2 days, pretreated with indicated inhibitors, and stimulated with 
EGF (10 nM) for 24 h or HGF (10 ng/mL) for 5 min. Cell lysates were analyzed for c-Met 
tyrosine phosphorylation and total c-Met expression. (B) After 2 h pretreatment with the c-Met 
inhibitors, SU11274 (1 µM) or PF2341066 (1 µM), cells were growth factor treated. (D) 201T 
cells were pretreated with either SU11274 or PF2341066 (1 µM) followed by stimulation with 
EGF (10 nM) for 5 min.  Cell lysates were immunoprecipitated for EGFR and probed for pY99 
and total EGFR. 
 
2.2.4 C-Src is a Key Biphasic Mediator in Signal Transmittance from EGFR to c-
Met. 
 
 The Src family kinases (SFK) are a group of non-receptor tyrosine kinases 
including c-Src, which are downstream regulators of tumorigenic phenotypes [119] 
Members of this family, particularly c-Src, have been identified as key intermediaries in 
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regulating lateral RTK-RTK signaling [76]. Because of these data and observations of c-
Met tyrosine phosphorylation, we hypothesized that the SFKs are critical signaling 
molecules in delayed EGFR activation of c-Met in NSCLC. To identify the presence of 
SFK members, we assessed protein expression in the lung cancer cell lines. It was 
observed that c-Src was ubiquitously expressed across our NSCLC cells with A549 cells 
expressing the higher level (Fig. 7).  
 Activation of c-Src is known to be downstream of EGFR [120]. Therefore, we 
assessed the response to EGF stimulation at delayed time points corresponding with c-
Met phosphorylation by measuring levels of activated c-Src in 201T cells. Interestingly, 
EGF activated c-Src in a biphasic manner (Fig. 12). The initial activation of c-Src was 
still present 2 h post-EGF stimulation and was subsequently reduced to near baseline 
levels by 4 h, while the second wave of much greater activation was initiated 8 h post-
treatment and lasted 48 h. This pattern of c-Src phosphorylation suggests a temporal 
association between delayed, persistent c-Src activation and delayed, persistent c-Met 
activation following EGF stimulation.  C-Met may be utilizing c-Src to amplify and 
prolong signaling from EGFR.   
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Figure 12. C-Src is phosphorylated at delayed time points. 201T cells were serum deprived for 
2 days followed by addition of EGF (10 nM) for 0-48 h. (A) Cell lysates were 
immunoprecipitated for total c-Src and analyzed for phospho-c-Src (Y418). IgG lane represents 
immunoprecipitation conditions with only IgG and Protein A Beads without experimental lysate.  
 
 We explored whether inhibition of the SFKs could inhibit EGFR-induced c-Met 
phosphorylation. To address whether c-Src and the SFKs were necessary, pan-SFK 
inhibitors, PP2 and dasatinib, were employed. A 2 h pretreatment with either PP2 or 
dasatinib blocked all EGF-induced c-Met phosphorylation while having minimal effect 
on increased total c-Met protein in response to HGF (Fig. 13a). In contrast, neither PP2 
nor dasatinib showed any direct inhibitory effect on c-Met autophosphorylation (Fig. 
13b) demonstrating that the SFKs are an intermediary needed for lateral signaling from 
EGFR to c-Met.  
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Figure 13. C-Src mediates EGFR-induced c-Met phosphorylation. 201T cells were pretreated 
for 2 h with SFK inhibitors (A) PP2 (500 nM) or (B) dasatinib (50 nM) prior to 24 h EGF (10 
nM) or 5 min HGF (10 ng/mL) stimulation. Cell lysates were prepared and analyzed for phospho- 
and total c-Met levels. 
 
 To discern whether c-Src, specifically, might be the key mediator, 201T cells 
were stably transfected with either a dominant-negative c-Src construct or an empty 
vector plasmid as published previously in Liu, et al [121]. Stimulation of DN-Src cells 
for 24 h with EGF resulted in a 2 to 3-fold decrease in total c-Met phosphorylation 
compared to 201T EV cells (Fig. 14). These experiments advocate that c-Src is a likely 
candidate molecule that is involved in both initializing EGFR – c-Met trans-activation as 
well as being a downstream mediator of delayed c-Met activation, although participation 
of other SFKs in some of the effect cannot be excluded. 
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Figure 14. Dominant negative c-Src impedes EGF-induced c-Met phosphorylation. (A) 201T 
cells were stably transfected with either a dominant-negative c-Src construct (DN-Src) or empty 
vector (EV), and serum deprived for 2 days followed by addition of EGF (10 nM) for 24 h. Cell 
lysates were prepared and analyzed for phospho- and total c-Met levels. (B) Relative quantitation 
of c-Met phosphorylation compared to total c-Met protein. 
 
2.2.5 C-Src Associates with c-Met at time points corresponding with c-Met 
Activation. 
 
 C-Src is activated downstream of c-Met through Src homology-2 domain 
association with c-Met phospho-tyrosines residues Y1349 or Y1356 following HGF 
ligand stimulation [59, 120]. We also observed that c-Src was continually activated at 
later time points. Therefore, we examined whether c-Src could interact with c-Met after 
exogenous EGF addition. Through co-immunoprecipitation studies following 24 h EGF 
stimulation, we found that c-Src can associate with activated c-Met in 201T cells 
suggesting that c-Src activity at 8 h – 48 h time points is mediated downstream of c-Met 
(Fig. 15). 
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Figure 15. C-Met associates with c-Src following 24 h EGF stimulation. C-Src was 
immunoprecipitated from EGF (10 nM) or HGF (10 ng/mL) stimulated 201T cells and 
immunoblotted for total c-Met and total c-Src levels. Non-immune IgG was used as an 
immunoprecipitation control. 
 
2.2.6 C-Met can be Tyrosine Phosphorylated by c-Src In Vitro. 
 
 Because c-Src was activated and could associate with c-Met at time points 
corresponding with c-Met activation, we aimed to determine whether c-Src could directly 
phosphorylate c-Met. It has been hypothesized that c-Src has the potential to 
phosphorylate c-Met; however, no direct evidence exists [76]. After a BLAST homology 
search, it was identified that homology exists between EGFR-Y845, a site known to be 
phosphorylated by c-Src, and the autophosphorylation site on c-Met, Y1234 (Fig. 16).  
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Figure 16. BLAST align search for EGFR and c-Met protein homology. 
 
 To test whether c-Src can phosphorylate c-Met in vitro, we developed a c-Src 
kinase assay system utilizing c-Met as a substrate. Total c-Src was immunoprecipitated 
from 5 min EGF-stimulated 201T cells, while non-activated c-Met was 
immunoprecipitated from unstimulated 201T cells. The c-Src kinase and c-Met substrate 
were incubated together with ATP and phosphorylated c-Met was measured through 
phospho-tyrosine immunoblotting. It was observed that c-Met can be directly 
phosphorylated by c-Src in the presence of ATP (Fig. 17). This data demonstrates that it 
is possible that c-Src can directly associate with and phosphorylate c-Met in our signaling 
paradigm, though subsequent experimentation suggests that a linear signaling cascade 
directly linking c-Src to c-Met activation is unlikely. 
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Figure 17. C-Met can be tyrosine phosphorylated by c-Src in vitro. 201T cells were stimulated 
with EGF (50 nM) for 5 min, while another plate was unstimulated. From the EGF-treated cells, 
total c-Src was immunoprecipitated and total c-Met was immunoprecipitated from the 
unstimulated cells. These samples were then co-incubated simultaneously with the Protein A-
Agarose Beads. Samples were incubated with 0.2 mM ATP for 15 min at 37°C. After the kinase 
reaction, samples were immunoblotted for phosphorylated c-Met as assessed by pY99 
immunoblotting, total c-Met, and total c-Src levels. 
 
 
2.2.7 Increased c-Met Tyrosine Phosphorylation and Protein through EGFR 
Requires New Gene Transcription. 
 
 EGF-induced c-Met tyrosine phosphorylation proceeds after pronounced 8 h 
delay. We hypothesized that such a delay was required in order to upregulate a yet 
identified intermediary in this signaling cascade. To test whether new gene transcription 
was required, 201T cells were pre-treated with the pan-transcription inhibitor, 
actinomycin D, prior to EGF administration. Inhibition of transcription abolished delayed 
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EGF-induced phosphorylation of c-Met, while having no effect on direct activation by 
HGF (Fig. 18a). This demonstrates that a transcriptional component is required for EGFR 
trans-phosphorylation of c-Met.  
 In addition to c-Met tyrosine phosphorylation, we also measured a 1.5-2.5-fold 
rise (p<0.0005) (Fig. 18b and 18c) in total c-Met protein and a corresponding 2-4-fold 
increase (p<0.005) (Fig. 18d) in c-Met transcript levels suggesting that the increase in c-
Met protein following EGF addition was a result of new gene transcription. Pretreatment 
with actinomycin D inhibited the increase in total c-Met protein confirming that the 
increase in c-Met expression through the EGFR pathway was due to new c-Met 
transcription (Fig. 18a). 
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Figure 18. EGF stimulation induces c-Met phosphorylation and increased c-Met mRNA and 
protein through new gene transcription. (A) 201T cells were serum starved 2 days, pretreated 
with actinomycin D (0.01 mg/mL), and treated with either EGF (10 nM) for 24 h or HGF (10 
ng/mL) for 5 min. Cell lysates were analyzed for c-Met tyrosine phosphorylation and expression. 
(B) 201T cells were serum-deprived for 2 days prior to stimulation with EGF (10 nM), TGF-α 
(10 nM), or HGF (10 ng/mL) for 0-48 h followed whole lysate western blotting with total c-Met 
and β-Actin antibodies. (C) Relative quantitation of total c-Met protein increase compared to β-
Actin at 24 h following EGF (10 nM) stimulation in 201T cells. ***, P < 0.0005 Student's t test. 
(D) 201T cells were treated with EGF (10 nM) for 0-48 h. Total mRNA was harvested and 
subjected to c-Met quantitative RT-PCR using β-Gus as an internal control. **, P < 0.005 
Student's t test. 
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2.2.8 C-Src Inhibition does not Block EGF-Induced c-Met Protein Increase. 
 
 It has been hypothesized that c-Met dimerization and activation can result from 
increased c-Met expression [83, 84]. Because c-Src signaling is critical to EGFR 
phosphorylation of c-Met, we assayed whether c-Src activation through EGFR was 
required for elevated c-Met mRNA and protein levels as well. Surprisingly, blockade of 
c-Src by SFK inhibitor, PP2, had no significant effect on EGF-induced c-Met transcript 
levels and c-Met protein (Fig. 19). This suggests that c-Src is not upstream of the modest 
increase in c-Met protein, but may be upstream of other critical transcriptional events 
regulating c-Met tyrosine phosphorylation.  
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Figure 19. C-Src does not mediate EGFR-induced total c-Met increase. A549 and 201T cells 
were pretreated for 2 h with PP2 (500 nM) prior to 24 h EGF stimulation. (A and B) mRNA was 
harvested, and subjected to c-Met quantitative RT-PCR using β-Gus as an internal control. (C) 
Cell lysates were prepared and analyzed for total c-Met and β-Actin levels. (D) 201T cells were 
pretreated for 2 h with dasatinib (50 nM) prior to 24 h EGF (10 nM) or 5 min HGF (10 ng/mL) 
stimulation. Cell lysates were prepared and analyzed for total c-Met and β-Actin levels. 
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2.2.9 HGF Autocrine Signaling is not Responsible for EGFR-induced c-Met 
Phosphorylation. 
  
 HGF autocrine loops have been observed in many tissue types; therefore, analysis 
of HGF production and secretion was performed at time points corresponding with c-Met 
phosphorylation induced by EGF in NSCLC cell lines. 201T and A549 cells were treated 
with EGF under serum-free conditions and tissue culture media was harvested for HGF 
ELISA. No HGF secretion was detected in any of the time point samples, suggesting that 
autocrine signaling is not occurring (Fig. 20a). To confirm this observation, mRNA was 
harvested from 201T cells following exposure to EGF, and HGF levels were measured. 
The results from the qRT-PCR assay showed no presence of the HGF transcript produced 
in unstimulated or stimulated NSCLC cells. (Fig. 20b). A neutralizing antibody to HGF 
also did not block the EGF-induced phosphorylation of c-Met (Fig. 20c). Based on these 
data, HGF itself is not involved in the EGF-initiated c-Met lateral signaling.   
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Figure 20. EGFR activation of c-Met does not require HGF production or secretion. A549 
and 201T cells were serum starved 2 days prior to stimulation with EGF (10 nM). (A) Tissue 
culture media was harvested for 0-24 h time points and subjected to HGF ELISA with fibroblast-
conditioned media (FCM) as a positive control. (B) Cells were treated, mRNA was harvested, and 
subjected to HGF quantitative RT-PCR using β-Gus as an internal control. Normal lung fibroblast 
(NLF) mRNA was utilized as a positive control while the breast cancer cell line, MCF-7, was 
used as a negative control for HGF expression. (C) EGF (10 nM) or HGF (10 ng/mL) was 
pretreated for 2 h with HGF neutralizing antibody or IgG control (300 ng/mL) prior to addition to 
201T cells for 24 h. Cell lysates were prepared and analyzed for phospho- and total c-Met levels. 
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2.2.10 The Pathway for Lateral EGFR to c-Met Signaling Does not Require a 
Secreted Factor. 
 
 C-Met is a central molecule that can be activated through various modes of cross-
talk signaling from cell surface proteins such as the integrins, RON, RET, plexin B1 as 
well as others including many G-protein-coupled receptors [77]. In order to begin to 
uncover other possible intermediates in this signaling cascade from EGFR to c-Met, we 
measured whether conditioned media from 24 h EGF stimulated 201T cells could induce 
c-Met phosphorylation of another set of serum-deprived 201T cells. Through whole cell 
lysate immunoblotting for phospho-c-Met (Y1234/35), phosphorylation of c-Met was 
identified in the initial 24 h EGF treated cells (Fig. 21 - Lane 9). It was also observed that 
media harvested from the 24 h EGF-treated 201T cells did not induce c-Met 
phosphorylation on serum deprived 201T cells up to 48 h (Fig. 21). Taken together, our 
findings favor an intracellular signaling cascade in the lateral signaling from EGFR to c-
Met, and the transcription of an as-yet unidentified protein that is responsible for delayed 
c-Met phosphorylation. 
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Figure 21. Conditioned media from EGF-treated 201T cells does not induce c-Met 
phosphorylation. Initial 201T cells were serum starved 2 days prior to stimulation with EGF (10 
nM) for 2 h, and the media was replaced with fresh serum free media for an additional 22 h. After 
the total 24 h, 201T conditioned media was harvested and placed on other serum starved 201T 
cells for 0-48 h. Whole cell lysates were prepared and analyzed for phospho- and total c-Met 
levels in both initial cells (lane 8) and conditioned media-treated cells.    
 
 
2.3 CONCLUSIONS AND DISCUSSION 
 
 In these series of experiments, we present findings that the mechanism of lateral 
communication from EGFR to c-Met relies on a delayed activation of c-Met that is 
dependent on c-Src. These findings provide an alternative working model of c-Met 
activation by EGFR in NSCLC cell lines expressing wild-type, non-amplified EGFR and 
c-Met. Here, EGFR ligands induce prolonged c-Met tyrosine phosphorylation after a 
pronounced delay that is not attributable to an HGF ligand autocrine pathway. 
Additionally, we have ruled out the secretion of other factors that might trigger c-Met 
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phosphorylation because conditioned media experiments could not replicate the EGF-
induced effect.  
 Our results suggest a model for lateral signaling from EGFR to c-Met involving 
intracellular signaling that is initiated by rapid c-Src activation, requires gene 
transcription, and leads ultimately to enhanced prolonged c-Src activation that is most 
likely downstream of c-Met (Fig. 22). While increased c-Met transcription was observed 
following EGF treatment of NSCLC cells, along with a modest increase in total c-Met 
protein, this increase in c-Met protein levels appears not to be solely responsible for the 
delayed c-Met phosphorylation because it is independent of c-Src activity.  Based on a 
recent report, the rise in protein level may be attributed to induction of new c-Met 
transcripts through EGFR activation of the HIF-1α pathway [85]. Moreover, earlier 
studies in thyroid carcinoma cells and human gastric carcinoma suggested that increased 
c-Met levels alone might lead to receptor activation, but concluded that there was a 
requirement of additional factors to achieve phosphorylation [83, 84]. We hypothesize 
that after EGFR stimulation, c-Src-dependent transcription of an unknown signaling 
intermediate accompanies the c-Met increase and is needed for delayed activation of c-
Met. Having ruled out secreted factors, the most probable mechanism is the involvement 
of production of an additional kinase, an inhibitor of a phosphatase, or a scaffolding 
molecule that could cause ligand-independent c-Met dimerization [122].  
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Figure 22. Mechanistic model of EGFR-induced c-Met activation in NSCLC. 
 
 C-Src is activated downstream of both EGFR and c-Met following direct ligand 
stimulation [59, 120]. Here, we showed that delayed c-Src activation is coupled with 
delayed EGF-induced c-Met phosphorylation, and that c-Src complexes with c-Met at 
time points after EGF stimulation that correspond to c-Met activation. This occurs when 
EGFR is no longer activated. The most likely explanation is that c-Src is activated 
downstream of c-Met through Src homology-2 domains associating with a distinct 
population of c-Met at phospho-tyrosines residues Y1349 or Y1356 [59]. Although it has 
been shown that c-Src can signal to HIF-1α, c-Src is minimally involved the pathway we 
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studied because PP2 had almost no effect on c-Met protein and mRNA levels following 
EGF stimulation [123]. This suggests that in the NSCLC cell studies, c-Src-dependent c-
Met phosphorylation is a distinct event from c-Met upregulation. This is the first time c-
Src has been implicated as a critical intermediary linking EGFR activation to c-Met 
phosphorylation. 
 It was also measured that c-Src is able to directly phosphorylate c-Met in an in 
vitro model system. Despite this observation, we strongly believe that although this 
happens in an cell-free kinase assay, it is unlikely that this is applicable to the c-Src role 
in transmittance of signal from EGFR to c-Met. A large reason for this hypothesis is that 
c-Src is typically activated in a transient manner, and it is doubtful that c-Src is able to 
remain activated downstream of EGFR alone for 8 h without a reinforcing loop. Taken 
together our findings suggest that c-Src initial activation through EGFR initiates a 
signaling cascade for transcriptional upregulation of a yet-identified intermediate that 
activates, and sustains, phosphorylation of possibly an intracellular population of c-Met 
receptors (Early observation). This delayed c-Met activation is then necessary to re-
activate c-Src to between 8 h and 48 h to potentially modulate invasive growth 
phenotypes.  
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3.0 EGFR PHENOTYPES REQUIRE C-MET 
 
3.1 Introduction 
 
 It has been well-documented that both EGFR and c-Met initiate very similar 
downstream effector molecules in signaling cascades that modulate pathways related to 
tumor growth and metastasis. The critical pathways have been well documented and 
include the K-Ras/MAPK, PI3K/AKT, β-catenin/E-cadherin, and STAT pathways 
amongst many others (Fig. 4). Moreover, many studies have demonstrated that cross-talk 
amongst pathways can occur particularly to escape receptor blockade. In these cases, the 
initiating signal for downstream activation is shuttled from one RTK to another as the 
tumor continues to progress.  
 Lateral signaling has been identified between c-Met and other molecules 
including EGFR and RON through varying mechanisms. These studies have implicated 
lateral activation of c-Met to be required for multiple phenotypes such as cell migration, 
cellular invasion, angiogenesis, and cell survival [77]. Despite these many studies in a 
variety of model systems, little is known regarding the impact of delayed and prolonged 
activation of c-Met through EGFR on known EGF-induced biological outcomes of cell 
migration, invasion, and proliferation. Based on our observations of delayed c-Met 
activation by EGF, we hypothesized that c-Met mediates at least part of the EGFR-
induced invasion, motility, and proliferation that leads to tumor progression. 
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3.2 RESULTS 
 
3.2.1 C-Met siRNA Specifically Reduces c-Met Expression in 201T Cells. 
 
 In addition to c-Met TKI inhibition with PF2341066, we also aimed to down-
regulate c-Met activity using RNAi. The extent of c-Met protein reduction was measured 
by transient c-Met siRNA transfection. Knockdown of c-Met by siRNA pool resulted in a 
92% specific reduction of c-Met compared to the non-targeting siRNA pool, while 
having no effect on c-Src levels (Fig. 23). 
 
 
 
Figure 23. C-Met siRNA specifically decreases c-Met protein levels in 201T cells. 201T cells 
were mock transfected or treated with either non-targeting siRNA (NT) or c-Met siRNA for 8 h. 
After 48 h, cell lysates were prepared and analyzed for total c-Met levels, c-Src, and β-Actin. 
***, P < 0.0005; **, P < 0.005 Student's t test. 
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3.2.2 The c-Met Inhibitor, PF2341066, and c-Met siRNA Block EGF-induced 
NSCLC Cell Invasion  
  
 The HGF/c-Met signaling cascade is critical to regulating complex signaling 
pathways required for cellular invasion; therefore, it was measured whether c-Met was 
required to mediate the known EGFR phenotypes of invasion. 201T and A549 NSCLC 
cell lines were pre-treated with the specific c-Met inhibitor, PF2341066 (1 µM), prior to 
EGF exogenous addition. PF2341066 treatment significantly reduced EGF-induced 201T 
and A549 cellular invasion by 86% at 48 h. and HGF-induced invasion by 98% in both 
cell lines (Fig. 24a-c).  
 To confirm findings that c-Met is required to fully modulate EGF-induced 
invasion, experiments were repeated with c-Met siRNA. C-Met down-regulation with 
siRNA resulted in similar results to the PF2341066 at 48 h in EGF-induced invasion 
experiments, where a 77% reduction in EGF-induced invasion was observed in 201T 
cells (Fig. 24d). As a control, HGF-induced invasion was inhibited by 86% by siRNA 
knockdown (Fig. 24d). These findings demonstrate that EGFR requires c-Met to activate 
the EGFR phenotypes of invasion in NSCLC cell lines.  
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Figure 24. EGFR relies on c-Met for maximal induction of EGFR invasion. Cells were serum 
deprived for 24 h prior to all 48 h invasion assays stimulated with EGF (50 ng/mL) or HGF (50 
ng/mL). For experiments involving PF2341066 (1 µM), cells were pretreated with the c-Met 
inhibitor or DMSO for 2 h. For c-Met siRNA transfection experiments, 201T cells were plated 
and subjected to non-targeting siRNA or c-Met siRNA. Following transfection, cells were serum 
deprived in 24-well Matrigel invasion chambers. 201T (A and B) and A549 cells (C) were plated 
in Matrigel invasion chambers with growth factors added to the lower chamber only. Invading 
cells of three independent experiments were counted by light microscopy at 10X magnification. 
(D) Invasion assays were repeated in 201T cells with c-Met or non-targeting siRNA knockdown 
as described previously. Mean of three independent samples per treatment group. ***, P < 
0.0005; **, P < 0.005; *, P < 0.05 Student's t test. 
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3.2.3 PF2341066 and c-Met siRNA Block NSCLC Cell Migration Initiated through 
EGFR  
 
 In addition to invasion, activation of downstream effector molecules by EGFR 
and c-Met lead to enhanced cellular migration. Therefore, we assessed whether c-Met 
was required, in some capacity, for EGF-induced migration. Cell migration initiated 
through EGFR, as assessed by wound healing assay, was inhibited with PF2341066 by 
81% and 57% in 201T and A549 cells, respectively (Fig. 25a-c). As a control, HGF-
stimulated migration was inhibited by 95% in 201T cells and 92% in A549 cells (Fig. 
25b-c). C-Met down-regulation with siRNA reduced EGF-induced wound healing by 
53% in 201T cells (Fig. 25d). HGF stimulated cell migration was inhibited by 86% (Fig. 
25d). These experiments substantiate that EGFR, in some capacity, requires c-Met to 
fully carry out the known phenotype cell motility.  
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Figure 25. EGFR relies on c-Met for maximal induction of EGFR cell migration. Cells were 
serum deprived for 24 h prior to all 48 h invasion assays stimulated with EGF (50 ng/mL) or HGF 
(50 ng/mL). For experiments involving PF2341066 (1 µM), cells were pretreated with the c-Met 
inhibitor or DMSO for 2 h. For c-Met siRNA transfection experiments, 201T cells were plated 
and subjected to non-targeting siRNA or c-Met siRNA. Following transfection, cells were serum 
deprived in 12-well plates for wound healing assays. 201T (A and B) and A549 cells (C) were 
grown on 12-well plates prior to serum starvation and wounding. Addition of ligands followed c-
Met inhibitor pretreatment or siRNA knockdown. Wounds were imaged at 0 and 48 h by 10X 
light microscopy. Migrating cells were measured by comparing 48 h wound size to initial wound 
size and expressed as percent wound closure.  (D) Would healing assays were repeated in 201T 
cells with c-Met or non-targeting siRNA knockdown as described previously. Mean of at least 
three independent samples per treatment group. ***, P < 0.0005; **, P < 0.005; *, P < 0.05 
Student's t test. 
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3.2.4 C-Met Inhibition has Modulating Effects on Cell Proliferation through EGFR. 
 
 EGFR and c-Met are both known to induce cell proliferation in a variety of cell 
model systems following an activating stimulus. Because we demonstrated that invasion 
and migration induced through EGFR required c-Met activation, it was hypothesized that 
EGF-induced cell proliferation required lateral signaling as well. Pre-treatment with the 
c-Met inhibitor, PF2341066, significantly reduced EGF-induced cell proliferation by 
30% in 201T cells and 51% in A549 cells as assessed by cell counting assays.  
Interestingly, HGF-induced proliferation was only significantly inhibited by 31% in the 
201T cell line, although a decreasing trend was observed in the A549 cells, where a 47% 
reduction was measured (Fig. 26).  
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Figure 26. PF2341066 partially inhibits EGF-induced cell growth. 201T and A549 cells were 
serum deprived for 24 h prior cell counting assays stimulated with EGF (50 ng/mL) or HGF (50 
ng/mL). For experiments involving PF2341066 (1 µM), cells were pretreated with the c-Met 
inhibitor or DMSO for 2 h. After 48 h, cells were harvested by trypsinization and 8 fields were 
counted with a hemocytometer at 10X magnification by light microscope. Mean of three 
independent samples per treatment group. *, P < 0.05 Student's t test. 
 
 We attempted to replicate these findings utilizing the c-Met siRNA pool in BrdU 
incorporation assays measuring the number of proliferating cells. The down-regulation of 
c-Met compared to non-targeting control decreased EGF-induced proliferation at 48 h as 
assessed by BrdU assay in 201T cells (Fig. 27). It is interesting to note that EGF addition 
merely induced a 1.5 fold increase in cell growth in the non-targeting siRNA cells. This 
is in accordance with previous findings that EGFR wild-type cells expressing at moderate 
levels are not “addicted” to EGFR activation for cell growth [124]. It is necessary that a 
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more sensitive EGFR ligand system and further replicates of these cell proliferation 
experiments be completed before a precise conclusion can be formulated.    
 
 
 
Figure 27. C-Met siRNA knockdown partially inhibits EGF-induced cell proliferation. For 
c-Met siRNA transfection experiments, 201T cells were plated and subjected to non-targeting 
siRNA or c-Met siRNA. Following transfection, cells were re-plated and serum deprived in 96-
well plates for cell proliferation assays. EGF treatment (50 ng/mL) was applied every 24 h over 
the 48 h time course. For the final 2 h, BrdU labeling solution was added to each well, cells were 
fixed, stained with an anti-BrdU antibody, and analyzed in triplicate in a plate reader at 490 nm 
wavelength. 
 
3.2.5. C-Met Inhibition does not Affect EGF Modulation of pMAPK, pAkt, and E-
cadherin 
 
 Receptor tyrosine kinase signaling pathways such as those initiated through 
EGFR and c-Met show a high level of overlap in the activation of key downstream 
effector molecules such as MAPK (proliferation/migration/invasion), Akt (survival), and 
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E-cadherin (migration/invasion) (Fig 4). Knowing that EGFR requires c-Met to fully 
activate some EGFR phenotypes, we assessed whether c-Met was required for 
modulation of these overlapping effector molecules.  
 Inhibition of c-Met with PF2341066 was chosen over c-Met siRNA because TKI 
blockade inhibited all c-Met tyrosine phosphorylation. 201T cells were pre-treated with 
PF2341066 prior to EGF addition up to 24 h. C-Met targeting had no effect on rapid 
EGF-induced MAPK, suggesting that the ability of EGFR to initiate this signaling 
cascade is not affected by status of c-Met (Fig. 28).  We also observed that at extended 
time points (4 h) Akt was not phosphorylated downstream of EGFR. This was 
anticipated, as c-Met activation does not begin until 8 h following EGF stimulation, 
whereas MAPK and Akt phosphorylation occur very rapidly (5 min – 1 h) and are 
returned to basal levels by 24 h (Fig. 28). Moreover, with regard to MAPK signaling, we 
demonstrated conflicting evidence as to whether c-Met is necessary for EGFR-mediated 
cell proliferation (Fig. 26 and 27). It would be unlikely this process would occur without 
MAPK, since this signaling cascade is integral in coordination of cell growth. 
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Figure 28. C-Met inhibition has no effect on EGF-induced phospho-MAPK. 201T cells were 
serum-deprived for 2 days prior to 2 h pretreatment with PF2341066 (1 µM) followed by 
stimulation with either EGF (10 nM) or HGF (10 ng/mL). Cell lysates were analyzed for MAPK 
and Akt phosphorylation and expression. 
 
  E-cadherin is a cell surface protein that has an important role in cell 
adhesion. Upon stimuli such as EGFR ligands, E-cadherin is internalized and degraded 
allowing for cell detachment and cell movement [125].  We measured whether c-Met 
blockade could impede the down-regulation of E-cadherin following EGF stimulation. It 
was observed that PF2341066 pre-treatment had no effect on the EGF-induced decrease 
in E-cadherin at 24 h (Fig. 29).  
 Despite not identifying a specific molecule requiring lateral signaling to c-Met, 
pan-phospho-tyrosine immunoblotting of EGF-stimulated 201T cells pre-treated with 
PF2341066 provided early evidence that a yet-identified protein around 75 kDa requires 
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EGFR to c-Met signaling (Data not shown). Based on the pattern of migration of this 
protein, it was hypothesized that this band might represent phosphorylated STAT3.  
 
Figure 29. C-Met inhibition has no effect on EGF-modulated E-cadherin. 201T cells were 
serum-deprived for 2 days prior to 2 h pretreatment with PF2341066 (1 µM) followed by 
stimulation with either EGF (10 nM). Cell lysates were analyzed for E-cadherin expression. 
 
3.2.6 C-Met is Required for Prolonged STAT3 Activation. 
 
 The STAT family of proteins are a group of transcription factors that include 
STAT3 and are activated downstream of growth factor stimuli including EGF and HGF 
to upregulate genes related to invasion and cell growth [67, 68]. It was demonstrated that 
in NIH3T3 and Chang liver cells, HGF stimulation leads to delayed, and prolonged 
activation of STAT3; therefore, we assessed whether EGF required c-Met to fully induce 
STAT3 phosphorylation [126]. H1435 cells were pre-treated with PF2341066 prior to 
EGF addition up to 24 h. C-Met targeting reduced EGF-induced phospho-STAT3 levels 
to baseline (Fig. 30). This suggests that EGFR requires c-Met to prolong signaling 
through the STAT3 protein. The requirement of EGFR activation of c-Met to fully 
activate STAT3 might be necessary for EGF-induced invasion and motility. 
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Figure 30. Prolonged STAT3 phosphorylation requires EGFR to c-Met signaling. H1435 
cells were serum-deprived for 2 days prior to 2 h pretreatment with PF2341066 (1 µM) followed 
by stimulation with either EGF (10 nM). Cell lysates were analyzed for STAT3 phosphorylation 
(Y705) and total expression. 
 
3.3 CONCLUSIONS AND DISCUSSION 
 
 Activation of invasion and motility are hallmarks of EGFR signaling that drive 
lung tumor progression [127]. We showed that EGFR activation of invasive phenotypes 
relies largely on c-Met signaling through an HGF-independent pathway. A possible 
explanation is that EGFR utilizes c-Met as a second-in-line molecule not to initiate 
response, but to amplify the complex phenotypic programs following early activation by 
EGFR. We also anticipate that an alternative c-Met cascade is being activated at delayed 
time points, as MAPK and Akt are not phosphorylated at time points corresponding to c-
Met phosphorylation. This mode of signaling might occur through intracellular 
relocalization of a distinct population of c-Met molecules that do not associate with the 
Gab1 adaptor protein that is known to be required for prolonged MAPK activation [128]. 
 75 
Instead, the observed interaction between c-Met and c-Src, presumably at the c-Met 
multi-substrate docking site, might preferentially lead to prolonged c-Src activation of 
regulatory molecules responsible for invasion and cell motility (Fig. 31). It was 
confirmed that c-Src is integral in these processes as PP2 treatment abolishes c-Src-
mediated migration (Data not shown). 
 Another phenotype associated with EGFR-ligand stimulation leads to increased 
cell proliferation. Therefore, it was measured as to whether lateral signaling from EGFR 
to c-Met was required for EGF-induced cell growth. The results from this course of 
experimentation were varied. One outstanding complexity is the modest increase in cell 
number or proliferation (1.5-2.5-fold) observed following either EGF or HGF treatment 
over 48 h. This issue might be attributed to these cell lines expressing only modest levels 
of wild-type EGFR and non-amplified MET. It is hypothesized that for a certain cell 
model be “addicted” to a single receptor tyrosine kinase pathway, the receptor levels 
must exceed a modest level or harbor an activating mutation [124]. Perhaps if we were to 
utilize, or engineer, a system that had expressed higher concentrations of EGFR, a greater 
effect on proliferation would be seen with exogenous EGF addition. This, however, 
would move our research further from the intended model of study. Remaining with our 
cell model, EGF-induced MAPK phosphorylation was not attenuated by c-Met inhibitors. 
This was anticipated since MAPK phosphorylation through various stimuli remained up 
to 24 h, and did not correlate with c-Met activation by EGF. With this observation, we 
believe that lateral signaling from EGFR to c-Met is unlikely to influence canonical 
signaling cascades responsible for cell proliferation, as MAPK is a central molecule for 
this process. 
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 To carry out complex phenotypic alterations through EGFR, precisely coordinated 
events must be organized at the integration level of effector molecules. We examined 
whether lateral signaling from EGFR to c-Met modulated levels of phospho-STAT3 and 
E-cadherin, all of which are highly integral in invasive growth. Of these molecules, 
prolonged STAT3 phosphorylation appears to be the only molecule identified to date that 
requires EGFR to c-Met lateral communication. STAT3 activation has been well 
described in response to EGFR ligand stimulation and is believed to occur through a 
variety of mechanisms [129]. One particular mode is through direct c-Src and other SFK 
activation downstream of RTKs that was first described by Cao et al. using the v-Src 
oncogene [130]. The findings described in this study might greatly aid in tying our 
mechanistic studies described earlier together with the phenotypic responses of invasion, 
migration, and prolonged STAT3 phosphorylation. We initially hypothesized that 
activation of c-Met by EGFR is utilized by NSCLC cells to amplify and prolong c-Src 
signaling. This sustained signal downstream of c-Src would allow STAT3 to also 
persistently be phosphorylated in homodimer complexes and translocate to the nucleus 
for transcription upregulation, presumably of genes involved in invasive growth. 
Additional experimentation of this STAT3 hypothesis is required for specific pathway 
details; however, we have constructed a strong foundation for future investigations. 
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Figure 31. Model of c-Src mediated cell migration and invasion. Adapted from Yeatman, 
TJ. 2004). 
 
To identify other potential effector molecules regulated by EGFR to c-Met signaling, it 
appears that a combination of high-throughput techniques such as invasion-focused gene 
arrays and proteomics, to isolate and identify unknown bands, would be the best course 
of action. At the point that a additional downstream intermediaries is confirmed, we will 
have a greater understanding of the manner by which EGFR utilizes delayed and 
prolonged c-Met activation to regulate EGFR-initiated invasion and motility (Fig. 31).  
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4.0 COMBINATIONAL TARGETING OF EGFR AND C-MET IN VIVO 
 
4.1 INTRODUCTION 
 
 There is increasing evidence that c-Met and EGFR signaling pathways interact 
with one another at multiple cellular levels to circumvent therapeutic inhibition. In 
particular, Engelman et al. established that c-Met signaling is a driver of acquired EGFR 
tyrosine kinase inhibitors (TKI) resistance in EGFR mutant lung cancer cells and that 
inhibiting c-Met concurrently could circumvent survival signaling, thus increasing 
efficacy of EGFR TKIs [42]. Clinical responses to EGFR TKIs in NSCLC patients have 
produced variable results [131]. In East Asian populations, where there is a high rate of 
EGFR mutations (~40%), EGFR targeted therapies give a good response. In contrast, 
patients from western countries tend to have a low frequency of EGFR mutations (3-8% 
of all lung tumors) and respond poorly to EGFR TKIs [40].  
 The reason for such low response rates in wild-type EGFR tumors to EGFR TKIs 
is complex and multi-faceted. In tumors that are initially sensitive to erlotinib and 
gefitinib, secondary resistance mechanisms emerge following eradication of all sensitive 
tumors cells. It has been shown that the remaining cells contain a mutant EGFR 
harboring the EGFR TKI resistant T790M mutation then repopulate the tumor [45-48]. 
This EGFR mutation renders the tumor cells resistant to EGFR TKIs and confers a 
proliferative advantage. Primary, or intrinsic, resistance against EGFR therapeutics in 
lung cancer is associated mutant KRAS expression. These cells are inherently insensitive 
to many, if not all, RTK targeted therapeutics due to a tumor growth driving force 
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downstream of RTK activation [43, 44]. Other factors that might be responsible for 
EGFR TKI resistance is increased ligand production for other RTKs such as the HGF/c-
Met pathway allowing shuttling of required downstream signaling to this pathway. To 
these mechanisms, we include our findings of an intracellular pathway by which EGFR 
activates c-Met. In utilizing a combined first-line treatment regimen of EGFR and c-Met 
TKIs, it might be possible to block many of these intrinsic escape mechanisms, and as the 
tumor becomes resistant to EGFR TKIS, might still provide anti-tumor efficacy through 
c-Met blockade.   
 Often ATP-competitive TKIs have off-target effects due to similarly structured 
ATP binding pockets; however, an inhibitor with cross-reactivity against both EGFR and 
c-Met has not yet been identified. Therefore, we aimed to determine whether combined 
TKI therapy of EGFR (gefitinib) and c-Met (PF2341066) provided greater tumor growth 
inhibition compared to individual therapies in a wild-type EGFR and c-Met model of 
NSCLC. These experiments were to be initially performed in a 201T xenograft NSCLC 
model and then utilized in a lung orthotopic, bioluminescent murine model. The 
bioluminescent orthotopic model was to be created in order to use this combination of 
targeted agents in a more physiologically relevant environment and to decrease the 
number of mice utilized for experimentation. 
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4.2 RESULTS 
 
4.2.1 Combinational Targeting of c-Met and EGFR have Enhanced Anti-tumor 
Activity in a Xenograft Model of NSCLC. 
 
 The identification of delayed c-Met activation in NSCLC cells with wild-type 
EGFR, as in the case of a majority of NSCLC patients, provides a rationale for 
combining therapies to improve response to EGFR TKIs. To address whether 
combinational targeting of EGFR and c-Met pathways leads to enhanced anti-tumor 
effects, athymic nude mice bearing 201T flank tumors were treated with either gefitinib, 
PF2341066, combination, or vehicle for 5 d/wk for 3 weeks. PF2341066 alone at a dose 
of 50 mg/kg had no significant effect on inhibiting tumor xenograft growth, whereas 
gefitinib significantly reduced tumor volume by 51%. Combining TKI therapies 
produced a 66% decrease in tumor volume; a significantly greater effect compared to 
PF2341066 and gefitinib groups, individually (Fig. 32a). EGFR and c-Met targets were 
confirmed in treatment groups by immunohistochemistry (Fig. 32b). This enhanced effect 
of EGFR and c-Met combinational therapy observed in this preclinical NSCLC murine 
model provides early rationale that inhibiting downstream signaling through each RTK as 
well as lateral signaling might be an effective mode of therapy.  
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Figure 32. Simultaneous targeting of EGFR and c-Met causes enhanced 201T xenograft 
tumor growth inhibition. (A) 201T cells (2x106) were injected into nude mice on day 0. On day 
10, tumors were measured and experimental treatments were initiated. PF2341066 (50 mg/kg), 
gefitinib (150 mg/kg), and vehicle control (0.9% saline/1% Tween-80), were administered daily 
by oral gavage until day 28. (B) Representative immunohistochemistry of EGFR and c-Met target 
expression in treated 201T xenograft tumors. Stained tissue sections of xenograft tumors were 
imaged at 20X magnification. ***, P < 0.0005; **, P < 0.005; *, P < 0.05 Student's t test with 
Welch correction. Everything is compared to the vehicle except where indicated. 
 
4.2.2 Combinational Targeting of c-Met and EGFR have Decreased Ki-67 Staining 
in Xenograft Tumors. 
 
 Measurement of Ki-67 protein levels through immunohistochemistry was 
performed to identify the extent to which individual or combined treatments inhibited 
tumor proliferation. Ki-67 staining of xenograft tumors at 28 days revealed significantly 
fewer proliferating cells in PF2341066 and gefitinib groups individually, while the 
combination group had a significantly greater effect compared to the individual 
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treatments confirming the gross measurement of tumor volume (Fig. 33). Additionally, 
we assessed the number of apoptotic nuclei in 201T xenograft tumors through TUNEL 
(Terminal deoxynucleotidyl transferase dUTP nick end labeling) staining.  No difference 
was observed through analysis of stained tumor sections (Data not shown).  
 
 
 
Figure 33. Combinational Targeting of c-Met and EGFR have Decreased Ki-67 Staining in 
Xenograft Tumors. (A) Representative Ki-67 stained sections of xenograft tumor imaged at 20X 
magnification. (B) Quantitation of Ki-67 staining was performed by counting 5 fields at 40X 
magnification. n = 5; ***, P < 0.0005; **, P < 0.005; *, P < 0.05 Student's t test. Everything is 
compared to the vehicle except where indicated. 
 
4.2.3 201T and A549 NSCLC Cell Lines Stably Express Firefly Luciferase. 
 
 We then aimed to create a bioluminescent (firefly luciferase), orthotopic model of 
NSCLC, in which it would be possible to measure EGFR and c-Met combined 
therapeutic response in a more representative lung tumor environment. The first step in 
generating this model was to clone the firefly luciferase gene into a vector compatible 
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with retroviral production. The firefly luciferase gene was sub-cloned from the 
commercially available pGL3 vector into the pMSCVneo retroviral backbone. Retrovirus 
was produced and harvested from 293T cells then transduced into the A549 and 201T 
NSCLC cell lines. Luciferase expression was measured through an in vitro luciferase 
assay, and individual clones (201T- clone 1 and A549- clone 5) expressing the highest 
level of luciferase selected for implantation into nude mice (Fig. 34).   
 
 
  
Figure 34. Individual NSCLC cell clones express firefly luciferase. 201T and A549 luciferase 
or empty vector clones were selected under G-418 pressure for 4 week.  Cell lysates were 
prepared and injected with luciferin substrate. Bioluminescent signals were immediately 
measured using a luminometer. All values are expressed as relative light units. 
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4.2.4 201T and A549 Luciferase Cells can be Implanted into the Flank Region of 
Nude Mice, but not the Lungs. 
 
 To test whether the A549 and 201T luciferase cell lines could be detected in vivo 
with the IVIS Xenogen Imager, we implanted A549 and 201T luciferase cells (1x106) 
into the flank regions of athymic nude mice. Immediately following subcutaneous 
injection of the cells, a large cell bolus was observed in both the left (A549) and right 
(201T) hind regions (Fig. 35). As anticipated, a large percentage of cells died-off 1-week 
post-injection, but there were small tumors that were still identifiable through imaging. 
These tumors continued to develop over time until the mice were sacrificed at week 4. 
The difference in tumor size measured through bioluminescence is probably due to the 
greater luciferase expression in the A549 cells (4092 R.L.U.) compared to the 201T cells 
(988 R.L.U.). Ultimately, we demonstrated that both the 201T and A549 luciferase cells 
could be detected in vivo with the Xenogen Imager. 
 We then tested whether these luciferase NSCLC cells implanted into the lungs 
could be detected. A549 and 201T luciferase cells (1x106) were injected via tail vein into 
the lungs as demonstrated previously [132]. As before with the subcutaneous injection, a 
large number of luciferase cells were observed in the lungs with a small percentage of the 
cells being trapped in the tail immediately following injection (Fig. 35). Subsequent 
measurement of cellular luciferase activity in the lungs, did not register any expression up 
to 4 weeks post-implantation (Fig. 35). In accordance, gross analysis of lung blocks 
excised from implanted mice did not reveal tumors in the lungs. We did, however, 
observe luciferase activity in the tail from trapped cells. These findings suggest that all of 
 85 
the injected cells in the lungs were destroyed and perhaps more cells need to be injected 
in the future.  
 
 
 
Figure 35. Expression of bioluminescent A549 and 201T cells in nude mice. Luciferase 
expressing 201T and A549 cells (1x106) were implanted into nude mice through subcutaneous 
injection (S.C.) into the hind flank region (left-A549, right-201T) or intravenously (I.V.) into the 
tail vein on day 0. Mice were and imaged with the Xenogen IVIS Imager every 7 days for 4 
weeks. Representative images are shown.  
 
4.3 CONCLUSIONS AND DISCUSSION 
 
 In these studies, we focused our efforts on EGFR – c-Met communication in 
NSCLC cell lines expressing wild-type EGFR and c-Met. Through identification of a 
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dual-regulation paradigm of tumorigenic signaling from EGFR to c-Met, we further show 
that combining EGFR and c-Met TKIs provided an enhanced inhibition of tumor growth 
and a concurrent reduction in Ki-67 staining in 201T xenograft tumors. These results 
suggest a rationale for simultaneous targeting of EGFR and c-Met to short-circuit 
signaling cascades responsible for invasive growth initiated and maintained through both 
receptors as well as trans-activation from EGFR to c-Met. 
 Early findings established that identification of an over-expressed or hyper-
activated molecule in tumor cells might provide an opportunity for specific, single-agent 
therapy in NSCLC cancer. This observation appears to be true in the case of NSCLC 
tumors with certain activating EGFR mutations, where these cells are addicted to the 
EGFR pathway. However, more complex are the tumors that rely on yet-identified 
molecules or a multitude of input signals to drive cancer progression as the case in the 
201T cells that represent of the EGFR and c-Met wild-type model system. It is also 
important to note that this cell line does not have a K-Ras mutation.  To foreshadow the 
current decision-making process in a clinical setting, this tumor profile would require 
cytotoxic chemotherapy possibly in combination with EGFR and c-Met TKIs as a first-
line treatment. EGFR/c-Met TKI combinations are currently being tested in preclinical 
and clinical trials in a variety of cancer model systems, and the results appear promising 
[133-137]. This multiple targeted approach would circumvent some intrinsic mechanisms 
of resistance as well as delay the emergence of secondary resistance while hopefully 
decreasing individual dosing levels to decrease toxicity.   
 In this work, we identified a novel pathway through which EGFR can activate c-
Met, thus providing further rationale that this signaling can be an escape mechanism for 
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both EGFR and c-Met inhibition, individually. Targeting of c-Met and EGFR 
simultaneously resulted in enhanced tumor growth inhibition, through blockade of 
downstream signaling from each receptor as well as lateral signaling between EGFR and 
c-Met to block all tumor growth and potential escape pathways.   It would be intriguing 
to assess the expression of invasion markers such as FAK phosphorylation and MMP 
expression in this 201T xenograft experiment, or to further utilize a different model to 
study in vivo combination efficacy such as a tumor metastasis model to study disease 
progression. The rationale behind using this model is due to the requirement of EGFR to 
c-Met signaling for invasion and migration phenotypes.  
 We anticipated utilizing this combinational regimen in a bioluminescent, 
orthotopic model of NSCLC; however, our first efforts were unsuccessful. The 201T and 
A549 cells were created to stably express the firefly luciferase gene and effectively 
implanted into the flanks of nude mice where bioluminescence was observed. 
Unfortunately, despite observed luciferase activity in the lung immediately following 
injection, it could not be identified at any later time point. This suggests that the entirety 
of cells were cleared from the lung over time, and not that these cell lines were unable to 
hone to the lung. In the future, we will increase cell number from 1x106 to identify 
whether we can get any cells to remain in the lung following implantation.   
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5.0 DISCUSSION 
 
 The main goal of this project was to understand EGFR to c-Met lateral signaling 
in EGFR and c-Met wild-type NSCLC from mechanistic, phenotypic, and preclinical 
perspectives to provide rationale for the use of EGFR/c-Met TKI combinations in the 
clinic. To this end, we demonstrated that there is a dual mode of c-Met activation 
regulated by EGFR at the post-translational level with tyrosine phosphorylation as well as 
the expression level with increased total c-Met. The most novel finding is that full c-Met 
activation occurs 8 h following EGF treatment and is extended up to 48 h due to a 
requirement of new gene transcription for both phosphorylation and increased c-Met 
protein. C-Met tyrosine phosphorylation proceeds through an intracellular signaling 
cascade, where c-Src is critical for EGFR to c-Met signal transmittance. Moreover, c-Src 
associates with c-Met and is activated at time points corresponding with c-Met activation. 
We hypothesize that this mode of c-Met activation through EGFR is being utilized to 
amplify c-Src signaling for known EGFR biological consequences such as invasion and 
migration through STAT3 phosphorylation. Targeted inhibition of downstream signaling 
both through c-Met and EGFR as well as lateral signaling to c-Met, enhances tumor 
growth inhibition in a 201T xenograft model of NSCLC. Taken together, these findings 
will aid in the future development of combinational EGFR and c-Met TKI treatments in 
clinical trials for NSCLC tumors with a wild-type EGFR and c-Met profile (Fig. 36). 
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Figure 36. Hypothetical model of EGFR-induced c-Met activation in NSCLC: mechanism 
and biological consequences. 
 
Defining tumor characteristics through molecular profiling appears to be the future of 
NSCLC treatment decision-making and has been successful in predicting EGFR TKI 
sensitivity in EGFR mutant NSCLC tumors. This population, however, is the minority of 
NSCLC patients. EGFR wild-type tumors represent an overwhelming majority in both 
North American (90%) and East Asian populations (60%) [40]. Currently, the best 
available treatment options are cytotoxic chemotherapies such as carboplatin and 
cisplatin that might increase survival for 1-2 months despite toxic side effects [10-12]. As 
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the process of detecting driving forces behind this disease is ongoing, it is imperative that 
we continue to identify future potential agents or combinations to impede NSCLC tumor 
progression. 
 One combination study highlights the necessity for targeting multiple RTK inputs 
in glioblastoma multiforme. These data demonstrate that to completely abrogate survival 
signaling through the PI3K/Akt pathway, a cocktail of EGFR, c-Met, and PDGFR 
inhibitors must be employed [138]. This experiment may lend itself well to NSCLC 
therapy regiments where hyper-activity of EGFR and c-Met are observed clinically. 
Parallel with these findings, targeted inhibition of downstream effector molecules such as 
PI3K and MEK might eventually prove to be effective in the treatment of NSCLC [139, 
140].  
 Here, we demonstrate that EGFR and c-Met TKIs combined have a greater effect 
on blocking pathways responsible for xenograft tumor progression compared to each 
therapy alone. In this controlled and short exposure environment, we do not expect to 
observe secondary resistance developments, but in a clinical setting with a more diverse 
tumor cell population resistance might arise. As combination therapies move forward in 
the clinic, retrospective analyses should be strongly considered not only to identify 
sensitive tumors, but to also understand resistance to such therapies.    
 The identification of EGFR to c-Met lateral signaling that has no extracellular 
requirement also has important clinical implications in the development of HGF 
neutralizing antibodies such as L2G7 (Takeda) and AMG 102 (Amgen) [102, 141]. It 
might be anticipated that in NSCLC tumors with increased production of HGF from the 
surrounding mesenchymal cells, these targeted inhibitors might be somewhat successful. 
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However, cells insensitive to this therapy might upregulate EGFR to c-Met signaling to 
escape HGF neutralizing antibody blockade. Our laboratory is currently involved in 
preclinical experimentation to combine EGFR TKIs with HGF antibodies, and the early 
results look very promising (Early observations).  
 We demonstrated for the first time that c-Src is a key intermediate in EGFR to c-
Met activation, which we believe to not be through direct phosphorylation due to 
signaling kinetics, but rather by transcriptional upregulation of an unknown molecule. As 
an integral player in tumorigenesis and other cross-talk pathways, c-Src targeted 
inhibitors have been under therapeutic development [142]. It is of interest to our findings 
that dasatinib (BMS-354825, brand name Sprycel, Bristol-Myers Squib), a recently 
approved SFK ATP-competitive inhibitor for melanoma and certain soft tumors, has 
potent off-target specificity on many RTKs including EGFR [143]. This observation and 
in conjunction with our mechanistic observations, suggest that combinations of dasatinib 
with c-Met agents like PF2341066 might prove to be more effective in impeding EGFR 
and c-Met wild-type NSCLC tumor growth by blocking all three molecules in our 
identified pathway. 
 The mechanism involved in EGFR-dependent c-Met activation requires 
transcription of an unknown mediator that is downstream of c-Src for phosphorylation. 
Although we showed that the newly transcribed molecule is not HGF or another secreted 
factor, the exact identity of this protein, or molecule family, remains unknown. It is also 
strongly believed that this is not due to increased c-Met density resulting in passive 
phosphorylation. As referenced previously, the other possible scenarios involve the 
upregulation of either an additional tyrosine kinase, an inhibitor of a phosphatase, or a 
 92 
scaffolding molecule. In formulating a hypothesis as to the identity of this molecule, one 
issue that has allowed for little forward movement is the minimal precedence for delayed 
phosphorylation in general, and no previous data focused on extended c-Met signaling. 
The theory that we believe to be most plausible is the production of a phosphatase 
inhibitor. The foundation of this decision is based on empirical findings in addition to 
process of elimination. 
 The first possibility is that a produced scaffolding molecule facilitates interaction 
between two mature c-Met molecules bringing them in close proximity such that trans-
autophosphorylation can occur. There is precedence for this mode of signaling that 
describes the manner by which MAPK cascades function. KSRI is the scaffolding 
molecule that associates with Raf, MEK, and ERK to relay phosphorylation signals to 
one another rapidly [144]. In c-Met receptor activation such a mode of activation has not 
been identified.  For this active process to occur with c-Met, a protein or protein complex 
would have to interact with the intracellular region of each β-chain without interfering 
with the tyrosine kinase domain or the C-terminus tyrosine residues. For this reason, it 
seems unlikely that an active c-Met scaffold is being created. An alternative possibility is 
that there is transcription regulation of a tyrosine kinase molecule. 
 We initially hypothesized that c-Src could directly phosphorylate and activate c-
Met. Experimental evidence demonstrated that this could occur in an in vitro system (Fig. 
17). However, after many discussions with c-Src “experts”, it seems highly unlikely that 
this transpires in a cellular context. The extended c-Src phosphorylation that we observe 
might proceed in a biphasic manner following EGF addition (Fig. 12). This early finding 
suggests that c-Src might be phosphorylated at 2 h, phosphorylation is decreased at 4 h, 
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and re-emerges at 8 h corresponding with the time point of c-Met activation. If this were 
entirely upstream of c-Met phosphorylation, this would require EGFR activity to be 
biphasic or an additional tyrosine kinase to be involved to complete biphasic activation of 
c-Src. This is not observed following EGF addition (Fig. 8b). Thus, we hypothesize that 
the late stages of c-Src activation are through the c-Met signaling cascade and not re-
activation downstream of EGFR suggesting that c-Src direct phosphorylation of c-Met 
does not occur. Further experimentation will focus on testing this hypothesis. 
 If this unknown factor is a different kinase, the overlying question must be 
addressed, from where does the activating stimulus originate? It is possible that a kinase 
might be turned on immediately after post-translational processing, but kinases are 
typically activated in response to stimuli such as direct phosphorylation, dimerization, or 
binding of multiple protein domains that is observed with adaptor molecules. Additional 
evidence against an additional tyrosine kinase relies on data demonstrating that 
phosphorylation of c-Met is prolonged and sustained for up to 48 h after initial EGF 
stimulation (Fig. 8a and Fig. 9). Kinases without persistent stimulus or activating 
mutations are often activated in a transient manner to rapidly relay information 
downstream. In theory, if a kinase was produced as an active molecule, it would be 
appropriate that an inactivating signal would be quickly initiated. This would suggest that 
kinase production would also require a coordinating secondary signal to allow prolonged 
activation.    
 The most probable scenario is that prior to c-Met phosphorylation, inhibition or 
down regulation of a protein phosphatase transpires. In a given cell at any time, there is 
equilibrium of kinase and phosphatase activity ongoing. We believe that to produce such 
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prolonged c-Met tyrosine phosphorylation downstream of EGFR, the balance of 
phosphorylation addition and removal is tilted toward increased phosphorylation. For 
canonical c-Met signaling, phosphorylation is known to be turned off through 
proteosomal degradation of the c-Met receptor and increased phosphatase activity 
through interactions as the juxtamembrane region [145]. An interesting note is that these 
phosphatase molecules have higher affinities for the monomeric form of the c-Met 
receptor that diminishes as oligomerization occurs [146]. If proven true in our system, 
then it would be interesting to determine whether c-Met is forming homodimers 
downstream of EGFR activation as we have illustrated (Fig. 36).  
 There are existing issues with each of these hypotheses, and it is imperative that 
much more experimentation be performed in order to focus on other key molecules 
besides c-Src in this pathway. I believe that in moving forward, the biggest issue lies with 
the question, “how does direct c-Met phosphorylation occur?” To begin to identify the 
key molecules required for c-Met phosphorylation, I would suggest a multi-pronged 
approach. The first step is to identify the pathways and transcription factors activated 
downstream of EGFR and c-Src activation. This can be performed through literature 
mining of known transcription factors regulated downstream of c-Src in conjunction with 
experimentation comparing transcription factor levels of EGF-treated dominant-negative 
c-Src transfected cells with native NSCLC cells between 4 h and 8 h time points. Once 
the transcription factors have been narrowed down, further searches can be performed to 
identify which genes they regulate, and whether these gene products could potentially 
play a role in c-Met phosphorylation.  
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 To explore this question from an alternate angle, the interacting proteins with c-
Met can be assayed through co-immunoprecipitation experiments and mass spectrometry. 
Based on experimental evidence, it is anticipated that the critical molecule involved in c-
Met phosphorylation through EGFR would be interacting with c-Met between 6 h and 8 h 
following EGF stimulation. This time span would provide a window after new gene 
transcription through EGFR and just prior to observed c-Met phosphorylation (Fig. 8a). 
Though there are likely to be many molecules associated with c-Met, the proteins can be 
further narrowed by comparing EGF- and vehicle-stimulated cells. In utilizing these two 
methodologies of discovery, candidate molecules will be detected and targeted inhibition 
and RNAi technologies can be employed to confirm specific involvement in EGFR to c-
Met signal transduction.  
 Based on the body of work presented here, there is still a significant amount of 
work to be performed in understanding the impact of EGFR initiated c-Met 
phosphorylation. Our results showed a unique requirement of c-Met to mediate certain 
known EGFR phenotypes and determined that dual targeting of EGFR and c-Met 
simultaneously resulted in enhanced anti-tumor effects in a NSCLC xenograft model. 
Most importantly, we identified a novel pathway by which EGFR can communicate to c-
Met through what appears to be an intricate mechanism. These early findings are merely 
the tip of the iceberg. Further studies should provide exciting insights into the 
complexities of lateral signaling in NSCLC tumors. It is hoped that the key intermediates 
in this cascade can be exploited for individual or combinational therapeutic targeting to 
impede NSCLC progression and ultimately decrease the number of lung cancer deaths.  
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